



Journal of Carbohydrate Chemistry

ISSN: 0732-8303 (Print) 1532-2327 (Online) Journal homepage: http://www.tandfonline.com/loi/lcar20

Synthesis and Characterization of Some Novel Thiosemicarbazones of Substituted Benzaldehydes and N-(Hepta-O-Acetyl-β-d-Lactosyl)Thiosemicarbazide

Nguyen Dinh Thanh, Hoang Thi Kim Van & Truong Thi Thu

To cite this article: Nguyen Dinh Thanh, Hoang Thi Kim Van & Truong Thi Thu (2015) Synthesis and Characterization of Some Novel Thiosemicarbazones of Substituted Benzaldehydes and N-(Hepta-O-Acetyl-β-d-Lactosyl)Thiosemicarbazide, Journal of Carbohydrate Chemistry, 34:9, 514-544, DOI: 10.1080/07328303.2015.1114119

To link to this article: <u>http://dx.doi.org/10.1080/07328303.2015.1114119</u>



View supplementary material

đ	1	1	1
п			

Published online: 14 Dec 2015.



🕼 Submit your article to this journal 🗗



View related articles 🗹



則 🛛 View Crossmark data 🗹

Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=lcar20



Synthesis and Characterization of Some Novel Thiosemicarbazones of Substituted Benzaldehydes and N-(Hepta-O-Acetyl-β-D-Lactosyl)Thiosemicarbazide

Nguyen Dinh Thanh,¹ Hoang Thi Kim Van,² and Truong Thi Thu¹

¹Faculty of Chemistry, VNU University of Science, 19 Le Thanh Tong, Hoan Kiem, Ha Noi, Viet Nam ²Viet Tri University of Industry Tion Kien, Lam Thao, Phy. The Viet Nam

²Viet Tri University of Industry, Tien Kien, Lam Thao, Phu Tho, Viet Nam

GRAPHICAL ABSTRACT



A set of reaction conditions, including ionic liquids as catalysts, water as solvent and microwave-assisted heating method, had been investigated for the synthesis of hepta-O-acetyl- β -D-lactosyl thiosemicarbazones. Based on optimized conditions, namely, [HO(CH₂)₂NH₃][OAc] as catalyst, water as solvent and 300 W microwave power, a series of substituted benzaldehyde hepta-O-acetyl- β -D-lactosyl thiosemicarbazones was synthesized by reaction of hepta-O-acetyl- β -D-lactosyl thiosemicarbazide with the corresponding substituted benzaldehydes. The high yields of 90–97% were achieved. Almost all of the obtained thiosemicarbazones exhibited remarkable antibacterial activity against *Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermidis, Enterobacter, Escherichia coli, Pseudomonas aeruginosa* and *Klebsiella*

Received August 6, 2015; accepted October 26, 2015.

Address correspondence to Nguyen Dinh Thanh, Faculty of Chemistry, VNU University of Science, 19 Le Thanh Tong, Hoan Kiem, Ha Noi, Viet Nam. E-mail: nguyendinhthanh@hus.edu.vn

pneumonia in comparison with sulphamethoxazole and trimethoprim as drug references and antifungal activity against Aspergillus niger, Candida albicans and Saccharomyces cerevisiae in comparison with clotrimazole as drug reference. MIC values of the compounds range from 39.1 to 2500 μ g/mL for bacterial activity and from 0.25 to 25.6 μ g/mL for fungal activity.

Keywords Antibacterial; Antifungal; Ionic liquid; β -Lactose; Thiosemicarbazone; Microwave-assisted reaction

INTRODUCTION

Thiosemicarbazones are compounds that contain azomethine and thiourea bonds simultaneously. Thiosemicarbazone derivatives of monosaccharide and disaccharide have received considerable attentions because of their multifaceted properties. These compounds are known to possess a lot of interesting biological activities, such as antituberculosis,^[1] antimicrobial,^[2,3] antibacterial,^[4,11] anticancer,^[5,6] anticonvulsant,^[7] antidiabetic,^[8] antifungal,^[9] antitumor,^[10,11] cytotoxic,^[12] antioxidant,^[13–15] anti-dyslipidemic,^[15] and enzyme inhibitory activities.^[16] In general, thiosemicarbazone derivatives containing monosaccharide moiety have significant anti-microorganisms and antioxidant activities both *in vivo* and *in vitro*.^[13,14,16] On the other hand, sugar isothiocyanates are among the most versatile synthetic intermediates in carbohydrate chemistry.^[17,18] They can be converted into a broad spectrum of functional groups such as amide, isonitrile, carbodiimide, and also *N*-thiocarbonyl derivatives allowing, simultaneously, the covalent coupling of a quite unrestricted variety of structures to the saccharide moiety.

In several previous articles, the synthesis of substituted aromatic aldehyde/ketone N-(per-O-acetylated glucopyranosyl) were reported.^[17,13,14,20–28] These compounds were synthesized by reaction of N-(per-O-acetylglycosyl)thiosemicarbazides with the corresponding carbonyl compounds, however, thiosemicarbazones containing simultaneously disaccharide moiety and benzene ring have not been reported yet.

In recent years, ionic liquids have been used more and more frequently in chemistry as reaction and/or extraction solvents or as catalysts. Ionic liquids with imidazole ring could solubilize carbonyl compounds, alcohols, alkyl halides, and also transition metal complexes, depending on the anion and the alkyl group of the imidazolium cation.^[29–31]

It's known that the conventional catalysts for reactions between aldehydes or ketones and amines involve mainly organic and mineral acids, such as acetic acid and hydrochloric acid.^[1,3,6–10,12,13,16] The use of these catalysts often suffers from the drawbacks of prolonged reaction times, harsh and harmful reaction conditions, and sometimes difficulty in product separations. This problem needs to be addressed in carbohydrate synthesis because of the susceptibility of the derivatives of carbohydrates towards acids, especially strong acids. In reactions of peracetylated glucopyranosyl thiosemicarbazides,

this becomes extremely important due to the sensibility of acetate groups toward hydrolysis in the presence of strong acidic and basic catalysts. Therefore, we are especially interested in developing the use of inexpensive, simple and efficient catalysts in the synthesis of thiosemicarbazones having monosaccharide moiety. On the other hand, it's known that Brønsted-acidic task-specific ionic liquids (TSILs), which are the third generation of ionic liquids, are designed to replace traditional mineral or organic liquid acids as catalysts, such as sulfuric acid, hydrochloric acid, acetic acid, and *p*-toluenesulfonic acid in these chemical processes.^[32] Such acidic TSILs exhibit dual role, as solvents and as catalysts, in different organic reactions.^[33,44–48] In fact, the use of such Brønsted-acidic TSILs as catalysts is being developed and explored in many types of organic reactions. Our report is one of such contributions in development and exploration of ionic liquids in general and TSILs in particular.

Continuing previous studies on the synthesis and the reactivity of N-(per-O-acetyl-D-glycopyranosyl)thiosemicarbazides,^[13,28] in the present paper we report a systematic study on the synthesis, spectral characterization, and biological activities of a series of substituted benzaldehyde N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazones. The use of acids (acetic and hydrochloric) and piperidine, as well as ionic liquids, as catalysts was also investigated in this paper. The reaction was carried out by using conventional and microwave-assisted heating methods.^[34] The antibacterial and antifungal activities of these thiosemicarbazones against some microorganisms were evaluated.^[39-42]

RESULTS AND DISCUSSION

Chemistry

Required *N*-(2,3,6,2',3',4',6'-hepta-*O*-acetyl- β -lactosyl)thiosemicarbazide **3** was prepared from the corresponding isothiocyanate (Sch. 1) by a procedure similar to that used for other peracetylated glucopyranosyl thiosemicarbazides.^[15,23,24] It's known that the conversion of *N*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)isothiocyanate into the corresponding thiosemicarbazide could usually be carried out at below room temperature in aprotic solvents, such as dichloromethane^[15] and dioxane,^[23,24] due to the higher reactivity of peracetylated glucopyranosyl isothiocyanate^[13,15,23,24] in comparison with aromatic isocyanate^[35] towards water. Previously, we found that the conversion of peracetylated glycopyranosyl isothiocyanates into the corresponding thiosemicarbazides could be performed in a protic solvent, such as absolute ethanol, but the reaction must be performed at lower temperature (usually 7–10°C) to prevent the transformation of isothiocyanate compounds into thiocarbamic acid derivatives.^[8,35] We realized that the use of absolute ethanol as solvent for this reaction is of great advantage to work out the reaction due to low solubility of

these thiosemicarbazides in ethanol. For improvement of this reaction, we have used an 85% hydrazine solution^[13] instead of 100% hydrazine hydrate.^[15] In this way, *N*-(hepta-*O*-acetyl- β -lactosyl)thiosemicarbazide **3** was obtained from the corresponding isothiocyanate derivative **2** by reaction with 85% hydrazine hydrate (Sch. 1) using the similar procedure in anhydrous dichloromethane^[15] or in anhydrous dioxane.^[23,24] The advantage of using ethanol as a reaction solvent is that the thiosemicarbazide product is precipitated as soon as it is formed, hence the isolation of the product became easier, simply by filtering the product precipitates separated. A high yield of 96% was achieved.



Scheme 1: Synthesis of *N*-(hepta-*O*-acetyl- β -D-lactosyl)thiosemicarbazide **3**. Conditions: (*i*) NH₄SCN, TBAB, 50°C; 1 h; (*ii*) 85% hydrazine hydrate, EtOH, 7–10°C.

There are several methods for the synthesis of isothiocyanate of sugars.^[23,24,36–38] In this article, the precursor of 2,3,6,2',3',4',6'-hepta-O-acetyl- β lactosyl isothiocyanate **2** was prepared from 2,3,6,2',3',4',6'-hepta-O-acetyl- β lactosyl bromide **1** by reaction with lead thiocyanate in toluene^[36] or xylene.^[37] In this research, we used the reaction of this bromide derivative with dry ammonium thiocyanate in anhydrous acetonitrile with tetrabutylammonium bromide as transfer catalyst for 10 min under microwave-assisted irradiation (modified the Tashpulatov's method).^[23,24] This procedure is greener than the reported procedures^[25,26] which used harmful lead thiocyanate in toluene or xylene.

In the literatures, peracetylated glucopyranosyl thiosemicarbazones, in particular, and other sugars thiosemicarbazones, in general, were synthesized under severe conditions: heating with acidic catalysts, such as hydrochloric and acetic acids, in organic solvents, such as methanol, ethanol, and propanol.^[1–12,13–27] The reaction time of these protocols are usually lengthy (often from 2 h to 48 h). Therefore, the search for methods with smooth conditions is always laid out. First, we considered the reaction of peracetylated β -lactosyl thiosemicarbazide **3** with unsubstituted benzaldehyde **4a** (R = H), as a model reaction, under the conventional conditions for the synthesis of thiosemicarbazones (Sch. 2, Table 1, Procedure A). This procedure used absolute ethanol as solvent and glacial acetic acid as catalyst, and the reaction mixture was heated by the conventional heating method or microwave-assisted conditions. The product yield was 75% for 2 h under refluxing using conventional heating, while in the case of microwave-assisted heating, the reaction afforded a yield of 78% in only 5 min.



Scheme 2: Synthesis of benzaldehyde *N*-(hepta-*O*-acetyl- β -D-lactosyl)thiosemicarbazones **5a–s**. Conditions: (*i*) glacial acetic acid, EtOH, MW irradiation, 5 min; (*ii*) ionic liquid (HOCH₂CH₂NH₃)(OAc), water, MW irradiation, 2–3 min.

We have evaluated the effect of microwave power on reaction time and product yield for these reactions (Table 1). We found that, initially, pulses of 30 s of microwave irradiation at maximum power (800 W) were applied, but the yields were not reproducible, and that it was difficult to maintain the heating of the reaction mixture. Other high microwave powers from 600 W to 300 W were also evaluated, and the results were similar, except for at 450 W the yields were higher (78%). A similarly high yield (78%) was also achieved at microwave power of 300 W. The microwave power of 300 W was then chosen as the optimized one and continuous microwave irradiation was evaluated below.

We have also used concentrated hydrochloric acid and piperidine as catalysts in this reaction instead of glacial acetic acid (Table 2). The results obtained in Table 2 showed that the use of hydrochloric acid and piperidine did not give the desired products 5a, even if the mixture was heated for 10 min under microwave-assisted conditions. It is possible that HCl had blocked the free amino group in thiosemicarbazide, therefore its reactivity toward carbonyl functional group was lost, whereas piperidine could not activate the carbonyl group in benzaldehyde 4a.

Entry	Microwave power (Watts)	Yield (%) ^a	
1	800 ^b	60	
2	d00 b	70	
3	450 ^b	78	
4	300 b	78	
5	100 b	55	
6	Conventional heating $^{\circ}$	75 (for 2 h)	

Table 1: Different microwave powers used for synthesis of 5a from 3 and 4a

alsolated yields.

^bCatalyst: Glacial acetic acid, 1 mmol%; Solvent: absolute ethanol; 5 min MW irradiation. ^cCatalyst: Glacial acetic acid, 1 mmol%; Solvent: absolute ethanol; 2 h refluxing.

	5a : Yield (%) / Time (min) ^a			
Catalysts	In 96% ethanol	In water		
CH ₃ CO ₂ H ^b	78 / 5	18 / 10		
HCI acid °	N.A. / 10	N.A. / 10		
Piperidine ^b	N.A. / 10	N.A. / 10		
(Éṫ₃NH)HSO₄ ^b	50 / 2	50 / 2		
(Bmim)HSO₄ ^b	88 / 2	90/2		
(HO(CH ₂) ₂ NH ₃)(OAc) ^b	96 / 2	97 / 2		
(HSO ₃ -Bmim)(HSO ₄) ^b	80 / 2	82 / 2		
(Hmim)BF ₄ b	87 / 2	88 / 2		
	$Catalysts \\ CH_3CO_2H \ ^b \\ HCI acid \ ^c \\ Piperidine \ ^b \\ (Et_3NH)HSO_4 \ ^b \\ (Bmim)HSO_4 \ ^b \\ (HO(CH_2)_2NH_3)(OAc) \ ^b \\ (HSO_3-Bmim)(HSO_4) \ ^b \\ (Hmim)BF_4 \ $	$\begin{tabular}{ c c c c c } \hline & & & & & & & & & & & & & & & & & & $		

Table 2: Comparison of ionic liquids used	d as catalysts for model reaction in
Scheme 1 with $4a$ (R = H) at microwave	power of 300 W

^alsolated yields.

^bMolar ratio of the catalyst to benzaldehyde is according to the general procedure (see Experimental part).

^cfor Entry 2: 0.01 mL 36% HCI solution in water and absolute ethanol as solvent.

Continuing our study, we have investigated the catalytic capacity of obtained ionic liquids, such as $[Et_3NH]HSO_4$,^[51] $[Bmim][HSO_4]$,^[52] $[HO(CH_2)_2NH_3][OAc]$,^[53] $[HSO_3-Bmim][HSO_4]^{[54]}$ and $[Hmim][BF_4]^{[55]}$ in synthesis of thiosemicarbazones **5a** from thiosemicarbazide **3** and benzaldehyde **4a** (R = H), as the optimized microwave power (300 W) was used according to Table 2. Because some of the ionic liquids could be miscible with water, we have used water as solvent in these investigations instead of absolute ethanol. In addition, we found that the use of absolute ethanol or 96% ethanol did not change the product yields significantly, with 78% and 77% yields of **5a**, respectively. Based on these results, we decided to use 96% ethanol as solvent instead absolute ethanol in following investigations.

We found that almost all of these ionic liquids increased remarkably the yields of thiosemicarbazones and decreased the reaction time typically by 2 min. Table 2 indicated that, in almost all cases, the reaction that carried out in water gave the higher yield than the one in 96% ethanol, and that the product yields went up in the following order of these catalysts: $[Bmim][HSO_4]$ (50%) < $[HSO_3-Bmim][HSO_4]$ (82%) < $[Et_3NH][HSO_4]$ (86%) < $[Hmim][BF_4]$ (88%) < $[HO(CH_2)_2NH_3][OAc]$ (97%). Clearly, the ionic liquid $[HO(CH_2)_2NH_3][OAc]$ is the most suitable for the model reaction described above. Since then, we found that the ionic liquid $[HO(CH_2)_2NH_3][OAc]$ was the best catalyst for synthesis of thiosemicarbazones. On the other hand, when these ionic liquids were used as catalysts, the solvent change from 96% ethanol to water only alters the product yield inconsiderably. Thus, than advantage of using ionic liquids as catalysts is that the reactions could be carried out in water instead of 96% ethanol (Tables 2 and 3), making this process green.

Table 3: Different microwave powers for synthesis of 5a using ionic liquid $(HO(CH_2)_2NH_3)(OAc)$ as catalyst in water solvent

Entry	Microwave power (Watts)	Yield (%) ^{a,b}		
1	800	53		
2	600	67		
3	450	97.2		
4	300	97		
5	100	60		

^alsolated yields.

^bReaction time: 2 min. Molar ratio of the catalyst to benzaldehyde is according to the general procedure (see Experimental part).

Next, we have surveyed the effects of microwave power on the reaction yield when the ionic liquid $[HO(CH_2)_2NH_3][OAc]$ was used. The results listed in Table 3 indicated that, similarly to the case of using acetic acid as catalyst in the ethanol, the product yields were lower when the higher microwave powers were applied in comparison with in cases of the lower microwave powers. The yield of products **5a** were 97.2% and 97% in microwave powers of 450 W and 300 W, respectively. Therefore, the microwave power of 300 W was both energy-efficient and eco-friendly (using water as the reaction solvent).

Next, we surveyed further how the amounts of the catalyst might influence this reaction. When the amount of catalyst was reduced to 5 mol%, we found that the product performance decreased, although the reaction time was prolonged twice. When augmenting the amounts of moles of catalyst from 10 mol% to 20, 30, 40 and 50 mol%, respectively, the product yield did not change much, even if the reaction time was maintained or prolonged twice. However, the use of 40 mol%- and 50 mol%-amounts of this TSIL could raise the yield up to ~98%, so in general, the use of a large amount of the catalyst is not beneficial in this synthetic reaction. As such, the amount of catalyst 10 mol% is the most appropriate for this reaction (Table 4).

After the optimized conditions for the synthesis of thiosemicarbazone **5a** were discovered, we applied these optimized conditions, i.e., using ionic liquid $[HO(CH_2)_2NH_3][OAc]$ as catalyst, water as solvent and microwave power of 300 W, to the synthesis of other thiosemicarbazones **5b–t** (Table 5). The results from this table indicated that the obtained product yields by using TSIL as catalyst were higher than the ones obtained with acetic acid as catalyst whereas the reaction times were maintained equally or changed a little.

Next, we examined the reusability of the catalyst under microwaveassisted conditions using the model reaction of benzaldehyde **4a** with thiosemicarbazide **3** in the presence of 2-hydroxyethylammonium acetate (Table 5, Entry 1). For this purpose, the amount of reagents were raised up to 50 mmol and the amount of $[HO(CH_2)_2NH_3][OAc]$ was 50 mmol%. Once the reaction

Entry	TSIL,ª (mmol%)	Time (min)	Yields (%) ^b	
1 2 3 4 5 6 7 8 9 10 11 12	5 5 10 10 20 20 30 30 40 40 50 50	2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4	45 47 97 97.3 97.6 97.8 97.6 97.2 97.1 98 98 98 98.3	

Table 4: Effects of catalytic amounts of (HO(CH₂)₂NH₃)(OAc) on synthetic reaction of **5a** in water at microwave power of 300 W

 $^{\alpha}TSIL = (HO(CH_2)_2NH_3)(OAc).$

^blsolated yields. Molar ratio of the catalyst to benzaldehyde is according to the general procedure (see Experimental part).

Image: Table 5: Comparison of synthesis of benzaldehyde N-(peracetylated)
β -lactosyl)thiosemicarbazones 5a–s with acetic acid and (HO(CH ₂) ₂ NH ₃)(OAc) as
catalyst in microwave-assisted conditions

			CH ₃ CO ₂ H ^a		TS	IL ^b
Entry	Compd.	R	Yield (%) ^c	Time (min)	Yield (%) ^c	Time (min)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	5a 5bc 5d 5cd 5f 5g 5h 5j 5k 5n 5pq 5r 5s	H 4-NO ₂ 3-NO ₂ 2-NO ₂ 4-F 4-CI 3-CI 2-CI 4-Br 4-Me 4-iPr 4-OMe 3-OMe 2-OMe 4-OH 2-OH 3-OMe-4-OH 3-OEt-4-OH 4-NMe ₂	78 87 83 83 70 76 68 78 78 78 78 78 78 78 73 73 73 73 73 77 77	555555555555555555555555555555555555555	97 94 90 91 93 97 92 97 97 97 97 97 97 97 97 97 97 97 97 97	2 3 3 2 2 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2

^aIn 5 mL of 96% ethanol, otherwise, in 5 mL of water. ^bTSIL = $(HO(CH_2)_2NH_3)(OAc)$ in water. ^cIsolated yields. Molar ratios of the catalyst to benzaldehyde is according to the general procedure (see Experimental part).



Figure 1: Recycling of $(HO(CH_2)_2NH_3)(OAc)$ as catalyst for reaction of benzaldehyde 4a with thiosemicarbazide 3 under microwave-assisted conditions: 3 (50 mmol), 4a (50 mmol) and $(HO(CH_2)_2NH_3)(OAc)$ (50 mmol%).

was completed, precipitates was filtered out the water solution and washed with water to remove ionic liquid out to obtain the crude product. The watercontaining ionic liquid (this TSIL is soluble in water) was evaporated under reduced pressure and the ionic liquid was recovered and reused. The results of the first experiment and subsequent experiments were almost all consistent in yields after five runs without any loss of its activity (97%, 96%, 94%, 92% and 90%, Fig. 1).

prepared The structures of the substituted benzaldehyde N- $(2,3,6,2',3',4',6'-hepta-O-acetyl-\beta-D-lactosyl)$ thiosemicarbazones 5a-s were confirmed by their spectroscopic data. The IR spectra show characteristic absorptions in the range of 3540–3480 (ν_{OH}) and 3348–3159 cm⁻¹ (ν_{NH}), 1737–1753 ($\nu_{C=0}$ ester), 1216–1252 and 1044–1056 cm⁻¹ (ν_{COC} ester), 1367–1377 cm⁻¹ ($\nu_{\rm C} = s$), and 1580–1615 cm⁻¹ ($\nu_{\rm CH} = s$). In the ¹H NMR spectra, signal of proton NH-2 was found farther downfield in region of δ 11.74–10.69 ppm (in singlet) as this proton was deshielded by anisotropic effect of adjacent imine bond, whereas the signal in region of δ 8.72–8.44 ppm belongs to NH-4, which was split into a doublet by one neighboring proton on the carbon C-1' of lactose moiety. The coupling constant in this case was J =8.5–9.5 Hz. The protons of the disaccharide moiety had the signals in region of $\delta = 5.90-3.80$ ppm. The protons in the carbons C-1" and C-2" magnetically interacted with each other with the coupling constant of J = 7.5-8.0 Hz. This corresponded with β -(1 \rightarrow 4)-glycoside linkage between ring A and ring B in β -D-lactose (see Sch. 1). In addition, the spin-spin splitting pattern between H-3" and H-4" on ring B (D-galactose component) differed from the one between H-3' and H-4' on ring A (D-glucose component). The values of coupling constants were J = 2.5-3.75 Hz (in ring B) and J = 9.25-9.75 Hz (in ring A), respectively. The chemical shift of proton H-1' (on ring A) was in region of $\delta = 5.90-5.74$ ppm as triplet pattern. This proton also had similar interaction with proton H-2' with the coupling constant of J = 9.00-9.25 Hz. The value of this coupling constant was consistent with a 1,2-*trans* relationship between these protons and showed that synthesized hepta-*O*-acetyl- β -D-lactosyl thiosemicar-bazones had β -D-anomeric configuration. Proton in azomethine group showed a sharp peak at δ 7.97–8.18 ppm (CH = N) in singlet. The positions of resonance signals of protons NH-2, NH-4 and CH = N were affected significantly by the substituent nature on the benzene ring: the e-donating groups, such as 4-NMe₂, 4-OH, 4-OCH₃ and 4-CH₃, caused signal of proton NH-2 shifted to upfield region, and the e-withdrawing ones, such as 4-NO₂, 3-NO₂, 4-F, 4-Br, 4-Cl and 3-OCH₃ and 3-OCH₃-4-OH, caused this signal shifted to downfield region.

The ¹³C-NMR spectrum of compound **5a–s** showed the four-parted regions of signals at δ 179.7–169.1, 159.7–111.3, 82.1–61.5 and 21.7–20.2 ppm. Signals at δ 179.1–177.8 ppm belonged to the carbon atom in the C = S group. The acetyl groups in these compounds showed resonance at δ 171.7–169.1 ppm for carbonyl carbon atom and 21.7–20.2 ppm for the methyl carbon one. The presence of imine in molecule were confirmed by signal at δ 147.8–140.2 ppm, belong to carbon atom in the azomethine group. It was observed that the NMR signal of carbon atom in the imine group was affected by these substituents in the following trend: the e-donating groups, such as 4-NMe₂, 4-OH, 4-OCH₃ and 4-CH₃, caused signal shifted to upfield region, and the e-withdrawing ones, such as 4-NO₂, 3-NO₂, 4-F, 4-Br, 4-Cl and 3-OCH₃ and 3-OCH₃-4-OH, caused the carbon signal shifted to downfield region.

Biological Evaluation

Antibacterial Activity

Antibacterial activity studies on thiosemicarbazones **5a–s** showed that these compounds had mild to moderate antibacterial activity against the tested bacteria (Table 6). Moreover, all compounds are more active (lower MIC) than the references sulphamethoxazole and trimethoprim for the majority of tested bacteria. It's known that sulfamethoxazole (SMZ or SMX) is a sulfonamide bacteriostatic antibiotic^[43] and trimethoprim (TMP)-an antibiotic used mainly in the treatment of urinary tract infections.^[44] These drugs are most often used as part of a synergistic combination with trimethoprim in a 5:1 ratio in co-trimoxazole, and known under trade names such as Bactrim, Septrin, or Septra, Biseptol...^[45] Its primary activity is against susceptible forms of *Streptococcus, Staphylococcus aureus* (including MRSA-Methicillin-resistant *Staphylococcus aureus*), *Escherichia coli, Enterobacter* spp., *Klebsiella pneumoniae, Mycobacterium tuberculosis, Salmonella typhi* (typhoid fever) and oral

	Microorganisms/ MIC (μ g/mL)							
	Gro	Gram positive		Gram negative			Э	
Compound/Drug	B.s.ª	<i>S.a.</i> ª	S.e.ª	En.ª	E.c.ª	P.a.ª	K.p.ª	logP (calc.)
5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 5l 5m 5n 5o 5p 5q 5r 5s Ref. A ^b Ref. B ^c	1200 1200 1200 1200 1200 1200 1200 1200	225.1 112.7 215.3 225.5 58.3 185.7 435 433 235.4 245.8 255.1 175.7 215.3 165.7 245.4 181.7 228.4 176.7 235.4 19.5 2500	2500 1200 1200 1200 1200 435 435 435 435 435 1200 435 1200 435 1200 435 1200 435 1200 435 1200 435	435 225.4 435 225.4 215.5 185.4 187.1 275.2 435 245.9 435 245.9 435 215.3 435 215.3 435 215.3 435 215.6 3000 2500	435 225.4 225.4 47.5 63.5 54.5 85.7 87.7 58.3 185.2 182.0 187.4 175.8 165.1 155.2 190.3 174.7 185.7 3200 2500	225.4 185.7 185.7 185.7 58.3 185.7 58.3 185.7 55.3 58.8 165.7 58.3 177.1 155.3 58.3 177.1 155.3 58.3 185.1 58.3 155.5 3000 3000	185.1 175.3 156.4 183.7 172.1 175.3 39.1 185.7 58.3 39.1 39.1 175.9 39.1 175.9 39.1 195.1 39.1 195.1 39.1 188.4 39.1 156.2 1100	4.32 4.24 4.23 4.42 4.53 5.08 5.15 5.01 5.25 4.78 5.66 4.45 4.41 4.05 4.07 4.29 3.95 4.48 4.49 0.89 0.79

Table 6: Antibacterial activities of thiosemicarbazones 5a-s

^aB.s.: Bacillus subtilis; S.a.: Staphylococcus aureus; S.e.: Staphylococcus epidermidis; En.:Enterobacter; E.c.: Escherchia coli; P.a.: Pseudomonas aeruginosa; K.p.: Klebsiella pneumonia ^bRef. A: Sulphamethoxazole

^cRef. B: Trimethoprim

anaerobes.^[45,46] Sulfamethoxazole is commonly used to treat urinary tract infections.^[46] This drug is available as a generic medication and is not very expensive.

The corresponding MIC values of these references against tested bacteria were 3200, 19.5, 3000, 3000, 3200, 3000 and 156.2 μ g/mL (for sulphamethoxazole) and 3000, 2500, 58.32, 2500, 2500, 3000 and 1100 μ g/mL (for trimethoprim), respectively. The data in Table 6 also showed that thiosemicarbazones **5a-s** were more active references for almost all tested bacteria, *B. subtilis* MIC = 225.4–1200 μ g/mL, *S. aureus* MIC = 176.7–435 μ g/mL, *S. epidermidis* MIC = 435–2500 μ g/mL, *Enterobacter* MIC = 185.4–435 μ g/mL, *E. coli* MIC = 174.7–225.4 μ g/mL, *P. aeruginosa* MIC = 58.3–225.4 μ g/mL, *K. pneumonia* MIC = 39.1–195.1 μ g/mL, except *S. aureus* and *K. pneumonia*: MIC values of sulfamethoxazole for this bacterium were 19.5 μ g/mL and 156.2 μ g/mL, respectively. For trimethoprim, almost all tested bacteria were inhibited by these compounds more than reference, except *S. epidermidis*: MIC value in

Compound/Drug	A. niger	C. albicans	F. oxysporum	S. cerevisiae	logP (calc.)
5a 5b 5c 5d 5e 5f 5g 5h 5j 5h 5i 5j 5k 5j 5k 5l 5m 5n 5o 5p 5q 5r 5s Clotrimazole	25.6 19.5 7.7 25.6 25.6 7.8 19.5 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7.7 7	0.50 0.53 0.54 0.51 0.28 0.45 0.34 0.25 0.25 0.57 0.25 0.57 0.25 0.57 0.25 0.57 0.25 0.57 0.25 0.57 0.58 0.57 0.58 0.57 0.58 0.57 0.58	4.9 2.7 2.7 4.5 2.7 1.2 2.7 4.4 2.2 2.7 9.4 4.7 2.2 2.7 2.2 2.7 9.1 4.7 4.9	3.8 3.8 2.6 2.2 2.3 2.2 2.3 2.3 2.3 3.5 3.6 3.2 2.3 3.5 2.3 3.5 2.3 3.5 3.6 3.2 2.3 3.5 3.6 3.2 2.3 3.5 3.6 3.2 2.3	4.32 4.24 4.23 4.42 4.53 5.08 5.15 5.01 5.25 4.78 5.66 4.45 4.41 4.05 4.07 4.29 3.95 4.48 4.49 5.44

Table 7: Antifungal activities of thiosemicarbazones 5a-s

this case was 58.32 μ g/mL, whereas MIC values of thiosemicarbazones were in 425–2500 μ g/mL. Especially, the most active thiosemicarbazones against each bacterium were as follows: **5i** and **5j** against *B*. subtilis (MIC = 435and 225.4 μ g/mL, respectively), **5e** against *S. aureus* (MIC = 58.3 μ g/mL), **5g-k,m,o,q,s** against S. *epidermidis* (MIC = 435 μ g/mL each) and **5g,i-m,q** against K. pneumoniae (MIC = $39.1-58.7 \ \mu \text{g/mL}$), **5e-j** against E. coli (MIC = μ g/mL), **5f**,**i**,**j** against *P. aeruginosa* (MIC = 55.3–59.1 μ g/mL), and **5b**,**d**,**e**,**g**i,k,m,o,q,s against *Enterobacter* (MIC = 185.4–275.2 µg/mL). The increased activity of the synthesized compound comparing to the references, trimethoprim and sulphamethoxazole, could be explained by electron delocalization over the whole molecule. The other reason could be the increased lipophilic character of thiosemicarbazones 5a-s with log *P* in the range of 3.95 to 5.66, as compared to that of the references trimethoprim (log P = 0.79) and sulphamethoxazole (log P = 0.89), thus favoring the permeation of **5a–s** through the lipid layer of the bacterial membranes. It may be suggested that this molecule deactivate various cellular enzymes, which play a vital role in various metabolic pathways of these microorganisms.^[47]

Antifungal Activity

The biological data in Table 7 showed that, notably, almost all tested thiosemicarbazones **5a-s** had more remarkable activities against these fungi

C. albicans, F. oxysporum, and S. cerevisiae but were more resistant to A. niger than clotrimazole (the reference compound, MIC = 2.6, 0.32, 4.9 and 2.6 μ g/mL, respectively). Clotrimazole is an antifungal medication, commonly, used in the treatment of fungal infections, in both humans and other animals, such as vaginal yeast infections (candidiasis), oral thrush (oral candidiasis), and ringworm (dermatophytosis).^[48] This drug is on the WHO's list of Essential Medicines (the most important medication needed in a basic health system).^[49]

In case of fungus Aspergillus niger, all compounds were less active than clotrimazole (MIC = 2.6 μ g/mL), compounds **5a,b,d,e,g,m** had the worst ability to inhibit to this fungus (MIC = 13.2–25.1 μ g/mL), and the remaining compounds had medium activity (MIC = 7.3–7.8 μ g/mL) but were less active than clotrimazole. In case of fungus Candida albicans, almost all compounds were less active than clotrimazole (MIC = 0.42–0.58 and 0.32 μ g/mL, respectively), except **5g** is equipotent (MIC = 0.34 μ g/mL), **5e,h,i,m,o,p** are more active (MIC = 0.25–0.28 μ g/mL). Almost all thiosemicarbazones had activities similarly with clotrimazole against fungus *Fusarium oxysporum* (MIC = 2.4 g/mL), in that, the compounds **5b,c,e,f,g,i,j,m,o,p** have MIC = 2.2–2.4 μ g/mL, except thiosemicarbazone **5f** is the most active (MIC = 9.1 μ g/mL). Thiosemicarbazones **5a,b,j,k,l,n** were less active against *Saccharomyces cerevisiae* (MIC = 2.8–3.6 μ g/mL), and the remaining compounds were more active (MIC = 2.2–2.4 μ g/mL) than clotrimazole (MIC = 2.6 μ g/mL).

CONCLUSION

In conclusion, we evaluated in this research the catalysis capacities of selected ionic liquids in synthetic reactions of thiosemicarbazones having β -lactose moiety under microwave-assisted conditions. We have given an interestingly simple procedure, cleaner reactions, and use of inexpensive and reusable ionic liquids as catalysts in water, allowing for economic and environmental-friendly conditions. Almost all quantitative yields and simple isolation and purification procedures of the products make it a useful procedure for the synthesis of these compounds. Almost all obtained thiosemicarbazones exhibited the remarkable antibacterial activity against *B. subtilis*, *S. aureus*, *S. epidermidis*, *Enterobacter*, *E. coli*, *P. aeruginosa* and *K. pneumonia* and antifungal activity against *A. niger*, *C. albicans* and *S. cerevisiae*.

EXPERIMENTAL

All solvents, chemicals, and reagents were obtained commercially and used without purification. Melting points were determined by open capillary method

on STUART SMP3 instrument (BIBBY STERILIN, UK) and are uncorrected. FTIR spectra (KBr disc) were recorded on an Impact 410 FT-IR Spectrometer (Nicolet, USA). ¹H and ¹³C NMR spectra were recorded on Bruker Avance Spectrometer AV500 (Bruker, Germany) at 500 MHz and 125 MHz, respectively, using DMSO- d_6 as solvent and TMS as an internal standard. Mass spectra were recorded on mass spectrometer LC-MS LTQ Orbitrap XL (ThermoScientific, USA) in methanol using ESI method or AutoSpec Premier (Water, USA) using EI method. The entire microwave heating experiments were conducted under reaction conditions of power and temperature. Thin-layer chromatography was performed on silica gel pates 60F₂₅₄ No. 5715 (Merck, Germany) with ethyl acetate and light petroleum (bp 60–90°C) or toluene, and spots were visualized with UV light or iodine vapor. The synthesis of some task-specific ionic liquid was carried out by modifying procedure from a similar method in the literature, as described as below. The synthesis of [Bmim]BF₄ was reported previously.^[50] Other ionic liquids such as [Et₃NH]HSO₄,^[51] [Bmim][HSO₄],^[52] [HO(CH₂)₂NH₃][OAc],^[53] [HSO₃-Bmim][HSO₄]^[54] and [Hmim][BF₄]^[55] were prepared by the procedure modified the ones in the corresponding references as indicated. The ionic liquid was formed quantitatively and in high purity. Hepta-O-acetyl- β -D-lactosyl bromide **1** was prepared from β -lactose by the similar procedure by previously Lemieux's method.^[56]

Synthesis of 2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl isothiocyanate (2)

To the mixture of hepta-O-acetyl- β -D-lactosyl bromide **1** (7.0 g, 10 mmol) and dry ammonium thiocyanate (1.9 g, 25 mmol) in 50 mL of absolute acetonitrile was added tetrabutylammonium bromide (10 mmol%) under stirring. The mixture was then irradiated for 10 min at 600 W. Upon completion (monitored by TLC, the eluent solvent system was toluene/ethyl acetate 1:1 v/v), the precipitate was removed by filtration and the solvent was removed by distillation, the residue was dissolved in chloroform, and the solution was washed with water. The chloroform layer was dried over CaCl₂ and evaporated to dryness *in vacuo*, and the residue was crystallized from ether-hexane (2:1) to afford isothiocyanate **2** (6.09 g). Yield: 90%. M.p. 163–164°C; ref.^[57]: 163–165°C.

Synthesis of N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl) thiosemicarbazide (3)

To a solution of hepta-O-acetyl- β -D-lactosyl isothiocyanate **2** (6.77 g, 10 mmol) in 40 mL of absolute ethanol a solution of 85% hydrazine hydrate (10 mmol, 1.2 ml) in 10 mL of absolute ethanol was added dropwise slowly with stirring in 30 minutes so that the reaction temperature is below 10°C. The white precipitate appeared immediately when several drops of hydrazine

had added due to low solubility of this thiosemicarbazide in ethanol. The temperature of solution was maintained between $10-12^{\circ}$ C. The mixture was continued stirring at 20°C for 30 min. The solid product then was isolated by filtering with suction. The crude product was crystallized from 96% ethanol to afford thiosemicarbazide **3** (6.81 g). Yield 96%, mp 187–188°C; FTIR (KBr): ν (cm⁻¹) 3473, 3409, 3273, 1753, 1620, 1535, 1378, 1226, 1050; ¹H NMR (DMSO*d*₆): δ (ppm) 9.21 (s, 1H, NH-2), 8.09 (s, 1H, NH-4), 5.78 (s br, 1H, H-1'), 5.21 (d, 1H, J = 2.0 Hz, H-4''), 5.20 (s br, 1H, H-3'), 5.12 (dd, 1H, J = 10.25, 3.75 Hz, H-3"), 4.95 (t, 1H, J = 9.25 Hz, H-2"), 4.84 (t, 1H, J = 9.25 Hz, H-2"), 4.75 (d, 1H, J = 8.0 Hz, H-1"), 4.56 (s br, 2H, NH-1), 4.26 (d, 1H, J = 12.0 Hz, H-5'), 4.21 (t, 1H, J = 6.25 Hz, H-6'a), 4.01–4.00 (m, 3H, H-6'b, H-6''a, H-6''a) 6''b), 3.77–3.76 (m, 2H, H-4', H-5'), 2.09–1.93 (7s, 21H, 7×CH₃CO); ¹³C NMR $(DMSO-d_6): \delta$ (ppm) 182.1 (C = S), 170.2–169.1 (7C, 7×COCH₃), 99.7 (C-1"), 80.8 (C-1'), 76.1 (C-4'), 73.3 (C-5'), 72.6 (C-3'), 70.8 (C-2'), 70.4 (C-3''), 69.7 (C-5''), 68.8 (C-2''), 67.1 (C-4''), 62.3 (C-6'), 60.9 (C-6''), 20.6–20.3 (7C, 7×COCH₃); ESI-MS: 732.16 [M+Na]⁺, 710.18 [M]⁺, 331.31, 317.27; calc. for C₂₇H₃₉N₃O₁₇S = 709.20 Da; [M+Na] = 732.19 Da; Anal. calcd. for C₂₇H₃₉N₃O₁₇S: C, 45.70; H, 5.54; N, 5.92; S, 4.52. Found: C, 45.74; H, 5.51; N, 5.95; S, 4.50.

General procedure for synthesis of *N*-(2,3,6,2',3',4',6'-hepta-Oacetyl-β-D-lactosyl)thiosemicarbazones (5a-s)

Procedure A (under refluxing microwave-assisted conditions)

A mixture of N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemi carbazide **3** (1 mmol) and appropriate substituted benzaldehydes **4a-s** (1 mmol) in 5 mL of absolute ethanol was added the appropriate acid or base catalyst (1 mmol%, Tables 2, Entry 1–3, for evaluation of the corresponding catalysts) under stirring. The mixture was then irradiated for a certain time (Table 5, for synthesis of thiosemicarbazones **5a-s**). Upon completion (monitored by TLC, the eluent solvent system was toluene/ethyl acetate 1:1 v/v), the solvent was evaporated to one half the original volumes. The resulting colorless crystals were filtered by suction. The crude product when recrystallized from 96% ethanol to afford the title compounds **5a-s**.

Procedure B (under microwave-assisted conditions and TSIL as catalyst)

A mixture of N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemi carbazide **3** (1 mmol) and appropriate substituted benzaldehydes **4a-s** (1 mmol) in 5 mL of 96% ethanol was added the appropriate ionic liquid catalyst (1 mmol%, Tables 2 and 5, Entry 4–8, for evaluation of the corresponding catalysts) under stirring. The mixture was then irradiated for a certain time (Table 5, for synthesis of thiosemicarbazones **5a-s**). Upon completion (monitored by TLC, the eluent solvent system was toluene/ethyl acetate 1:1, v/v), the precipitated crude product was collected by filtration, washed by water and recrystallized from 96% ethanol to afford pure thiosemicarbazones **5a-s**. After removing off the water under reduced pressure to 5 mL volume, the filtrate containing the ionic liquid could be reused directly in the next run without further purification.

The products were confirmed by FTIR, ¹H NMR, ¹³C NMR, MS and physical data (m.p., $[\alpha]_D^{25}$).

Benzaldehyde N- $(2,3,6,2',3',4',6'-hepta-O-acetyl-\beta-D-lactosyl)$ thiosemicarbazone (5a)

From 709 mg of **3** and 106 mg of **4a**. Recrystallized from 96% ethanol to yield white crystals of **5a**. Yield: 622 mg, 78% (reaction time: 5 min, procedure A); 773 mg, 97% (reaction time: 2 min, procedure B); mp 158–159°C; $[\alpha]_{D}^{25}$ +85.4 $(c 1.0, CHCl_3); FTIR (KBr) \nu / cm^{-1}: 3469, 3304, 1750, 1605, 1369, 1222, 1051;$ ¹H NMR (DMSO- d_6): δ (ppm) 11.95 (s, 1H, NH-2), 8.67 (d, 1H, J = 9.5 Hz, NH-4), 8.10 (s, 1H, CH = N), 7.82–7.80 (m, 2H, H-2^{$\prime\prime\prime$} & H-6^{$\prime\prime\prime$}), 7.45–7.43 (m, 3H, H-3''', H-4''' & H-5'''), 5.86 (t, 1H, J = 9.25 Hz, H-1'), 5.31 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.19 (t, 1H, J = 9.5 Hz, H-2'), 5.15 (dd, 1H, J = 10.5, 3.5 Hz, H-3''), 4.87 (dd, 1H, J = 10.0, 3.0 Hz, H-2''), 4.80 (d, 1H, J = 10.0, JJ = 8.0 Hz, H-1''), 4.30 (d, 1H, J = 11.0 Hz, H-6'a), 4.26 (t, 1H, J = 6.75 Hz, H-5'', 4.07 (dd, 1H, J = 12.0, 5.5 Hz, H-6'b), 4.04 (dd, 1H, J = 6.25, 2.25 Hz, H-6"a), 4.03 (dd, 1H, J = 6.25, 2.25 Hz, H-6"b), 3.89 (ddd, 1H, J = 9.75, 5.75, $1.75 \text{ Hz}, \text{H-5'}, 3.80 \text{ (t, 1H, } J = 9.5 \text{ Hz}, \text{H-4'}, 2.11-1.90 \text{ (s, 21H, } 7 \times \text{COCH}_3);$ ¹³C NMR (DMSO- d_6): δ (ppm) 178.3 (C = S), 170.3–169.1 (7 × COCH₃), 143.7 5′′′), 99.6 (C-1′′), 81.2 (C-1′), 76.1 (C-4′), 73.3 (C-5′), 72.7 (C-3′), 71.1 (C-2′), 70.4 (C-3''), 69.7 (C-5''), 68.8 (C-2''), 67.1 (C-4''), 62.4 (C-6'), 61.0 (C-6''), 20.7–20.3 (7×COCH₃); ESI-MS: m/z: 820.34 [M+Na]⁺, 798.39 [M+H]⁺, 766.59, 738.50, 658.66, 541.45, 331.48; calc. for $C_{34}H_{43}N_3O_{17}S = 797.23$ Da. Anal. calcd. for C₃₄H₄₃N₃O₁₇S: C, 51.19; H, 5.43; N, 5.27; S, 4.02. Found: C, 51.23; H, 5.41; N, 5.25; S, 4.05.

4-Nitrobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5b)

From 709 mg of **3** and 151 mg of **4b**. Recrystallized from 96% ethanol to yield white crystals of **5b**. Yield: 732 mg, 87% (reaction time: 5 min, procedure A); 791 mg, 94% (reaction time: 3 min, procedure B); mp 172–173°C; $[\alpha]_D^{25}$ +79.8 (*c* 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3490, 3325, 1746, 1615, 1376, 1231, 1056; ¹H NMR (DMSO-*d*₆): δ (ppm) 12.16 (s, 1H, NH-2), 8.88 (d, 1H, *J* = 9.0 Hz, NH-4), 8.25 (d, 2H, *J* = 9.0 Hz, H-3''' & H-5'''), 8.18 (s, 1H, CH = N), 8.10 (d, 2H, *J* = 9.0 Hz, H-2''' & H-6'''), 5.88 (t, 1H, *J* = 9.0 Hz, H-1'), 5.31 (t, 1H, *J* = 9.0 Hz, H-1'), 5.31 (t, 1H, *J* = 9.0 Hz, H-1'), 5.31 (t, 1H, J) = 9.0 Hz, H-1''.

 $J = 9.25 \text{ Hz}, \text{ H-3'}, 5.24-5.21 \text{ (m, 2H, H-2' & H-4'')}, 5.15 \text{ (dd, 1H, } J = 10.0, 3.5 \text{ Hz}, \text{H-3''}), 4.88 \text{ (t, 1H, } J = 8.75 \text{ Hz}, \text{H-2''}), 4.80 \text{ (d, 1H, } J = 8.0 \text{ Hz}, \text{H-1''}), 4.31 \text{ (d, 1H, } J = 11.5 \text{ Hz}, \text{H-6'a}), 4.25 \text{ (t, 1H, } J = 6.5 \text{ Hz}, \text{H-5''}), 4.07 \text{ (dd, 1H, } J = 12.5, 5.5 \text{ Hz}, \text{H-6'b}), 4.03 \text{ (d, 2H, } J = 6.0 \text{ Hz}, \text{H-6''a & H-6''b}), 3.90-3.87 \text{ (m, 1H, H-5')}, 3.81 \text{ (t, 1H, } J = 9.25 \text{ Hz}, \text{H-4'}), 2.11-2.01 \text{ (s, 21H, } 7 \times \text{COC}H_3); 1^3\text{C} \text{ NMR} (\text{DMSO-}d_6): \delta \text{ (ppm) } 178.8 \text{ (C = S)}, 170.2-169.0 (7 \times \text{COCH}_3), 147.8 \text{ (C-4''')}, 141.1 \text{ (CH = N)}, 140.2 \text{ (C-1''')}, 128.4 \text{ (C-2''' & C-6''')}, 123.8 \text{ (C-3''' & C-5''')}, 99.6 \text{ (C-1'')}, 81.3 \text{ (C-1')}, 76.0 \text{ (C-4')}, 73.4 \text{ (C-5')}, 72.8 \text{ (C-3')}, 71.2 \text{ (C-2')}, 70.4 \text{ (C-3'')}, 69.7 \text{ (C-5'')}, 68.9 \text{ (C-2'')}, 67.1 \text{ (C-4'')}, 62.4 \text{ (C-6')}, 61.0 \text{ (C-6'')}, 20.7-20.3 (7 \times \text{COC}H_3); \text{ESI-MS: } m/z: 843.80 [M+H]^+, 840.91, 799.01, 668.15, 443.28, 366.45; calc. for C_{34}H_{42}N_4O_{19}S = 842.22 \text{ Da}$ Anal. calcd. for C₃₄H₄₂N₄O₁₉S: C, 48.45; H, 5.02; N, 6.65; S, 3.80. Found: C, 48.42; H, 5.06; N, 6.68; S, 3.83.

3-Nitrobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5c)

From 709 mg of 3 and 151 mg of 4c. Recrystallized from 96% ethanol to yield white crystals of 5c. Yield: 699 mg, 83% (reaction time: 5 min, procedure A); 758 mg, 90% (reaction time: 3 min, procedure B); mp 173–174°C; $[\alpha]_{D}^{25}$ +94.7 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3548, 3340, 1751, 1615, 1372, 1229, 1048; ¹H NMR (DMSO- d_6): δ (ppm) 12.10 (s, 1H, NH-2), 8.83 (d, 1H, J = 9.0 Hz, NH-4), 8.21 (s, 1H, CH = N), 8.58 (s, 1H, H-2''), 8.30 (d, 1H, J = 7.5 Hz, H-4''), 7.72 (d, 1H, J = 8.0 Hz, H-5'''), 8.24 (dd, 1H, J = 8.0, 1.5 Hz, H-6'''), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6'''), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')), 5.86 (t, 1H, J = 8.0, 1.5 Hz, H-6''')))9.0 Hz, H-1'), 5.31 (t, 1H, J = 9.0 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.20 (t, 1H, J = 9.5 Hz, H-2'), 5.15 (dd, 1H, J = 10.0, 3.5 Hz, H-3''), 4.88 (dd, 1H, J = 10.0, 3.5 Hz, H-3'')10.25, 8.25 Hz, H-2'', 4.80 (d, 1H, J = 8.0 Hz, H-1'', 4.31 (d, 1H, J = 11.0 Hz,H-6'a), 4.25 (t, 1H, J = 6.75 Hz, H-5"), 4.08 (dd, 1H, J = 12.0, 5.5 Hz, H-6'b), 4.04 (dd, 1H, J = 6.75, 2.25 Hz, 2H, H-6"a), 4.03 (dd, 1H, J = 6.75, 2.25 Hz, 2H, H-6"b), 3.91-3.84 (m, 1H, H-5'), 3.82 (t, 1H, J = 9.25 Hz, H-4'), 2.11-1.91(s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 178.7 (C = S), 170.2–69.1 $(7 \times COCH_3)$, 141.6 (CH = N), 148.4 (C-3'''), 135.7 (C-1'''), 133.4 (C-6'''), 130.2 (C-5"), 124.4 (C-4"), 121.9 (C-2"), 99.6 (C-1"), 81.3 (C-1'), 76.0 (C-4'), 73.5 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.4 (C-3''), 69.8 (C-5''), 68.9 (C-2''), 67.1 (C-4''), $62.4 (C-6'), 61.0 (C-6''), 20.7-20.3 (7 \times COCH_3); ESI-MS: m/z: 865.06 [M+Na]^+,$ 843.02 $[M+H]^+$, 823.13, 658.18, 331.21; calc. for $C_{34}H_{42}N_4O_{19}S = 842.22$ Da. Anal. calcd. for C₃₄H₄₂N₄O₁₉S: C, 48.45; H, 5.02; N, 6.65; S, 3.80. Found: C, 48.49; H, 5.00; N, 6.63; S, 3.78.

2-Nitrobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5d)

From 709 mg of **3** and 151 mg of **4d**. Recrystallized from 96% ethanol to yield white crystals of **5d**. Yield: 99 mg, 83% (reaction time: 5 min, procedure

A); 758 mg, 90% (reaction time: 3 min, procedure B); mp 170–172°C; $[\alpha]_D^{25}$ +87.2 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3473, 3295, 1751, 1615, 1373, 1230, 1048; ¹H NMR (DMSO- d_6): δ (ppm) 12.18 (s, 1H, NH-2), 8.77 (d, 1H, J = 9.0 Hz, NH-4), 8.53 (s, 1H, CH = N), 8.06 (d, 1H, J = 8.5 Hz, H-3^{'''}), 7.68 (t, 1H, J =7.5 Hz, H-4'''), 7.79 (t, 1H, J = 7.5 Hz, H-5'''), 8.38 (d, 1H, J = 7.5 Hz, H-6'''), 5.86 (t, 1H, J = 9.25 Hz, H-1'), 5.30 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 2H, H-3')3.5 Hz, H-4'', 5.20 (t, 1H, J = 9.5 Hz, H-2', 5.15 (dd, 1H, J = 10.25, 3.75 Hz, 3.75 Hz,H-3"), 4.87 (dd, 1H, J = 10.25, 8.25 Hz, H-2"), 4.80 (d, 1H, J = 8.0 Hz, H-1"), 4.30 (d, 1H, J = 12.0 Hz, H-6'a), 4.25 (t, 1H, J = 6.5 Hz, H-5''), 4.07 (dd, 1H, J)= 12.25, 5.75 Hz, H-6'b), 4.05-4.02 (m, 2H, H-6''a & H-6''b), 3.92-3.89 (m, 1H, 1-6) H-5'), 3.80 (t, 1H, J = 9.5 Hz, H-4'), 2.11–1.90 (s, 21H, $7 \times COCH_3$); ¹³C NMR $(DMSO-d_6): \delta$ (ppm) 178.8 (C = S), 170.2–69.0 (7×COCH₃), 148.4 (C-2'''), 138.9 (CH = N), 133.4 (C-5''), 130.8 (C-4''), 128.3 (C-6''), 128.1 (C-1''), 124.6 (C-6'')) $3^{\prime\prime\prime}$), 99.6 (C-1 $^{\prime\prime}$), 81.3 (C-1 $^{\prime}$), 76.0 (C-4 $^{\prime}$), 73.4 (C-5 $^{\prime}$), 72.7 (C-3 $^{\prime}$), 71.1 (C-2 $^{\prime}$), 70.4 (C-3"), 69.7 (C-5"), 68.9 (C-2"), 67.1 (C-4"), 62.3 (C-6"), 61.0 (C-6"), 20.6–20.2 $(7 \times \text{COCH}_3)$; ESI-MS: m/z: 865.19 [M+Na]⁺, 843.28 [M+H]⁺, 783.37, 658.41, 331.69; calc. for $C_{34}H_{42}N_4O_{19}S = 842.22$ Da. Anal. calcd. for $C_{34}H_{42}N_4O_{19}S$: C, 48.45; H, 5.02; N, 6.65; S, 3.80. Found: C, 47.49; H, 5.05; N, 6.68; S, 3.83.

4-Fluorobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5e)

From 709 mg of **3** and 124 mg of **4e**. Recrystallized from 96% ethanol to yield white crystals of 5e. Yield: 70 mg, 70% (reaction time: 5 min, procedure A); 733 mg, 91% (reaction time: 2 min, procedure B); mp 159–160°C; $[\alpha]_{D}^{25}$ +95.4 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3563, 3320, 1752, 1601, 1376, 1238, 1048; ¹H NMR (DMSO- d_6): δ (ppm) 11.90 (s, 1H, NH-2), 8.66 (d, 1H, J = 9.0 Hz, NH-4), 8.09 (s, 1H, CH = N), 7.88 (d, 2H, J = 8.5 Hz, $J_{HF} = 5.5$, H-2^{'''} & H-6^{'''}), 8.10 (d, 2H, J = 8.5 Hz, H-3^{'''} & H-5^{'''}), 5.85 (t, 1H, J = 9.25 Hz, H-1[']), 5.30 (d, 1H, J = 9.25 Hz, H-3', 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.19 (d, 1H, J = 9.25 Hz, H-3'')H-2'), 5.17 (dd, 1H, J = 9.75, 3.75 Hz, H-3"), 4.88 (dd, 1H, J = 10.5, 3.25 Hz, H-2"), 4.80 (d, 1H, J = 8.0 Hz, H-1"), 4.31 (d, 1H, J = 11.5 Hz, H-6'a), 4.25 (t, 1H, J = 6.5 Hz, H-5''), 4.07 (dd, 1H, J = 5.5, 11.0 Hz, H-6'b), 4.04-4.02 (m, 10.1)2H, H-6''a & H-6''b), 3.90-3.87 (m, 1H, H-5'), 3.81 (t, 1H, J = 9.5 Hz, H-4'), 2.11–2.01 (s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 178.4 (C = S), $170.2-169.1 (7 \times COCH_3), 163.3 (C-4'''), 142.6 (CH = N), 130.4 (J_{CF} = 11.4 Hz), 142.6 (CH = N), 130.4 (J_{CF} = 11.4 Hz), 142.6 (CH = N), 142.6 (CH = N)$ C-1^{'''}), 129.7 ($J_{CF} = 33.5 \text{ Hz}$, C-2^{'''} & C-6^{'''}), 115.7 ($J_{CF} = 87 \text{ Hz}$, C-3^{'''} & C-5^{'''}), 99.6 (C-1^{''}), 81.3 (C-1[']), 76.0 (C-4[']), 73.4 (C-5[']), 72.7 (C-3[']), 71.1 (C-2[']), 70.4 (C-3''), 69.8 (C-5''), 68.9 (C-2''), 67.1 (C-4''), 62.4 (C-6'), 61.0 (C-6''), 20.7–20.2 $(7 \times \text{COCH}_3)$; ESI-MS: m/z: 816.07 [M+H]⁺, 838.12 [M+Na]⁺, 784.41, 756.21, 640.29, 598.31, 331.18; calc. for $C_{34}H_{42}FN_3O_{17}S = 815.22$ Da. Anal. calcd. for C₃₄H₄₂FN₃O₁₇S: C, 50.06; H, 5.19; N, 5.15; S, 3.93. Found: C, 50.10; H, 5.16; N, 5.18; S, 3.91.

4-Chlorobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5f)

From 709 mg of 3 and 140 mg of 4f. Recrystallized from 96% ethanol to yield white crystals of **5f**. Yield: 632 mg, 76% (reaction time: 5 min, procedure A); 773 mg, 93% (reaction time: 2 min, procedure B); mp 189–190°C; $[\alpha]_D^{25}$ +100.2 (c 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3279, 3215, 1751, 1605, 1371, 1222, 1046; ¹H NMR (DMSO- d_6): δ (ppm) 11.95 (s, 1H, NH-2), 8.70 (d, 1H, J = 9.0 Hz, NH-4), 8.08 (s, 1H, CH = N), 7.85 (d, 2H, J = 8.5 Hz, H-2^{'''} & H-6^{'''}), 7.49 (d, $2H, J = 8.5 Hz, H-3''' \& H-5'''), 5.85 (t, 1H, J = 9.0 Hz, H-1'), 5.30 (t, 1H, J = 0.0 Hz, H_1'), 5.30 (t, 1H, J = 0.0 Hz, H-1'), 5.30 (t, 1H, J = 0.0 Hz, H$ 9.25 Hz, H-3', 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.20 (t, 1H, J = 9.25 Hz, H-2'), 5.16 (dd, 1H, J = 3.5, 10.0 Hz, H-3"), 4.88 (t, 1H, J = 9.0 Hz, H-2"), 4.80 (d, 1H, J = 7.5 Hz, H-1"), 4.30 (d, 1H, J = 11.5 Hz, H-6'a), 4.25 (t, 1H, J = 6.0 Hz, H-5"), 4.08–4.05 (m, 1H, H-6'b), 4.04–4.03 (m, 2H, H-6"a & H-6"b), 3.90–3.88 (m, 1H, H-5'), 3.80 (t, 1H, J = 9.5 Hz, H-4'), 2.11–1.91 (s, 21H, 7×COCH₃); ¹³C NMR (DMSO- d_6): δ (ppm) 178.3 (C = S), 170.5–169.4 (7×COCH₃), 142.7 (CH = N), 134.9 (C-4''), 132.5 (C-1''), 129.8 (C-2''' & C-6'''), 128.8 (C-3''' & C-6''')C-5'''), 99.6 (C-1''), 81.2 (C-1'), 75.9 (C-4'), 73.5 (C-5'), 72.6 (C-3'), 70.9 (C-2'), 70.3 (C-3''), 69.7 (C-5''), 67.0 (C-4''), 68.8 (C-2''), 62.2 (C-6'), 60.9 (C-6''), 20.5–20.1 (7×COCH₃); ESI-MS: m/z: 854.17/856.17, [M+Na]⁺]/[M+2+Na]⁺, $832.13/834.09 \ [M+H]^+]/[M+2+H]^+, 790.18, 656.27, 640.38, 598.39, 331.30;$ calc. for $C_{34}H_{42}{}^{35}ClN_3O_{17}S/C_{34}H_{42}{}^{37}ClN_3O_{17}S = 831.19/833.19$ Da. Anal. calcd. for C₃₄H₄₂ClN₃O₁₇S: C, 49.07; H, 5.09; N, 5.05; S, 3.85. Found: C, 49.11; H, 5.06; N, 5.08; S, 3.90.

3-Chlorobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5g)

From 709 mg of 3 and 140 mg of 4g. Recrystallized from 96% ethanol to yield white crystals of 5g. Yield: 565 mg, 68% (reaction time: 5 min, procedure A); 806 mg, 97% (reaction time: 3 min, procedure B); mp 152–153°C; $[\alpha]_{D}^{25}$ +88.7 (c 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3500, 3336, 1751, 1605, 1371, 1222, 1046; ¹H NMR (DMSO- d_6): δ (ppm) 11.99 (s, 1H, NH-2), 8.75 (d, 1H, J = 9.0 Hz, NH-4), 8.08 (s, 1H, CH = N), 7.98 (s, H-2''), 7.48-7.44 (m, 1H, H-4'''), 7.48–7.44 (m, 1H, H-5'''), 7.70 (dd, 1H, J = 7.0, 1.5 Hz, H-6'''), 5.85 (t, 1H, J = 9.0 Hz, H-1'), 5.30 (t, 1H, J = 9.0 Hz, H-3'), 5.24 (d, 1H, J =3.5 Hz, H-4'', 5.21 (t, 1H, J = 9.25 Hz, H-2', 5.16 (dd, 1H, J = 3.5, 10.0 Hz,H-3"), 4.88 (dd, 1H, J = 2.0, 8.0 Hz, H-2"), 4.80 (d, 1H, J = 8.0 Hz, H-1"), 4.31 (d, 1H, J = 11.0 Hz, H-6'a), 4.25 (t, 1H, J = 6.75 Hz, H-5"), 4.07 (dd, 1H, J = 5.75, 12.25 Hz, H-6'b), 4.04–4.00 (m, 2H, H-6''a & H-6''b), 3.89 (ddd, 1H, J = 1.5, 5.5, 10.0 Hz, H-5'), 3.81 (t, 1H, J = 9.5 Hz, H-4'), 2.11–1.90 (s, 21H, $7 \times COCH_3$; ¹³C NMR (DMSO- d_6): δ (ppm) 178.6 (C = S), 170.1–169.0 $(7 \times COCH_3)$, 142.2 (CH = N), 135.9 (C-1''), 133.7 (C-3''), 130.5 (C-4''), 129.8 (C-5'''), 126.7 (C-6'''), 126.3 (C-2'''), 99.6 (C-1''), 81.3 (C-1'), 76.0 (C-4'), 73.4 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.4 (C-3''), 69.7 (C-5''), 68.9 (C-2''), 67.1 (C-4''), 62.3 (C-6'), 61.0 (C-6''), 20.8–20.2 (7×COCH₃); ESI-MS: m/z: 854.22/856.12 [M+Na]⁺]/[M+2+Na]⁺, 794.36, 732.34, 658.33, 561.70, 473.73, 331.64; calc. for C₃₄H₄₂³⁵ClN₃O₁₇S/C₃₄H₄₂³⁷ClN₃O₁₇S = 831.19/833.19 Da. Anal. calcd. for C₃₄H₄₂ClN₃O₁₇S: C, 49.07; H, 5.09; N, 5.05; S, 3.85. Found: C, 49.05; H, 5.12; N, 5.03; S, 3.83.

2-Chlorobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5h)

From 709 mg of 3 and 140 mg of 4h. Recrystallized from 96% ethanol to yield white crystals of 5h. Yield: 648 mg, 78% (reaction time: 5 min, procedure A); 765 mg, 92% (reaction time: 3 min, procedure B); mp 187–188°C; $[\alpha]_{D}^{25}$ $+87.2 (c \ 1.0, \text{CHCl}_3); \text{FTIR} (\text{KBr}) \nu / \text{cm}^{-1}: 3309, 1750, 1615, 1375, 1223, 1050;$ ¹H NMR (DMSO- d_6): δ (ppm) 12.08 (s, 1H, NH-2), 8.75 (d, 1H, J = 9.0 Hz, NH-4), 8.52 (s, 1H, CH = N), 7.51 (dd, 1H, J = 8.0, 0.5 Hz, H-3"), 7.44 (td, 1H, J) = 8.0, 0.5 Hz, H-3"), 7.44 (td, 2H, J) 1H, J = 7.25, 2.0 Hz, H-4'''), 7.40 (t, 1H, J = 7.25''), Hz, H-5'''), 8.27 (dd, 1H, J = 7.5, 1.5 Hz, H-6'''), 5.86 (t, 1H, J = 9.0 Hz, H-1'), 5.30 (t, 1H, J =9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.0 Hz, H-4''), 5.23 (t, 1H, J = 9.25 Hz, H-2'), 5.15 (dd, 1H, J = 10.0, 3.5 Hz, H-3''), 4.87 (dd, 1H, J = 10.0, 3.0 Hz, H-2''), 4.80 (d, 1H, J = 8.0 Hz, H-1''), 4.33–4.30 (m, 1H, H-6'a), 4.25 (t, 1H, J = 6.75 Hz, H-5"), 4.06 (dd, 1H, J = 5.25, 12.25 Hz, H-6b), 4.03-4.02 (m, 2H, H-6'a & H-6''b), 3.90-3.88 (m, 1H, H-5'), 3.80 (t, 1H, J = 9.5 Hz, H-4'), 2.11–1.92 (s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 179.1 (C = S), 170.7–169.5 $(7 \times COCH_3)$, 140.2 (CH = N), 133.9 (C-1^{'''}), 132.1 (C-2^{'''}), 131.6 (C-4'''), 130.3 (C-3'''), 127.8 (C-5'''), 128.0 (C-6'''), 100.1 (C-1''), 81.7 (C-1'), 76.5 (C-4'), 73.9 (C-5'), 73.2 (C-3'), 71.6 (C-2'), 70.9 (C-3''), 70.2 (C-5''), 69.3 2''), 67.6 (C-4''), 62.8 (C-6'), 61.5 (C-6''), 21.2–20.8 (7×COCH₃); ESI-MS: m/z: $832.21/834.09 [M+H]^+/[M+2+H]^+, 790.17, 656.35, 640.38, 598.39, 331.28;$ calc. for $C_{34}H_{42}^{35}ClN_3O_{17}S/C_{34}H_{42}^{37}ClN_3O_{17}S = 831.19/833.19$ Da. Anal. calcd. for C₃₄H₄₂ClN₃O₁₇S: C, 49.07; H, 5.09; N, 5.05; S, 3.85. Found: C, 49.11; H, 5.05; N, 5.03; S, 3.88.

4-Bromobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5i)

From 709 mg of **3** and 185 mg of **4i**. Recrystallized from 96% ethanol to yield white crystals of **5i**. Yield: 683 mg, 78% (reaction time: 5 min, procedure A); 850 mg, 97% (reaction time: 2 min, procedure B); mp 155–156°C; $[\alpha]_D^{25}$ +78.9 (*c* 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3334, 1749, 1605, 1367, 1231, 1064; ¹H NMR (DMSO-*d*₆): δ (ppm) 12.00 (s, 1H, NH-2), 8.70 (d, 1H, J = 9.0 Hz, NH-4), 8.08 (s, 1H, CH = N), 7.82 (d, 2H, J = 8.5 Hz, H-2′′′ & H-6′′′), 7.66 (d, 2H, J = 8.5 Hz, H-3′′′ & H-5′′′), 5.90 (t, 1H, J = 9.0 Hz, H-1′), 5.24 (t, 1H, J = 9.25 Hz, H-2′), 5.33 (t, 1H, J = 9.25 Hz, H-3′′), 5.28 (d, 1H, J = 3.5 Hz, H-4′′), 5.16 (dd, 1H, J = 10.25, 3.75 Hz, H-3′′), 4.91 (dd, 1H, J = 11.5, 3.0 Hz, H-2′′)

4.83 (d, 1H, J = 8.0 Hz, H-1″), 4.33 (d, 1H, J = 11.0 Hz, H-6′a), 4.29 (t, 1H, J = 6.5 Hz, H-5″), 4.09 (dd, 1H, J = 12.0, 5.5 Hz, H-6′b), 4.07–4.05 (m, 1H, H-6″a), 3.94–3.91 (m, 1H, H-6″b), 3.93 (ddd, 1H, J = 9.75, 5.75, 1.75 Hz, H-5′), 3.84 (t, 1H, J = 9.75 Hz, H-4′), 2.15–1.94 (s, 21H, 7×COCH₃); ¹³C NMR (DMSO-d₆): δ (ppm) 178.4 (C = S), 170.2–169.0 (7×COCH₃), 142.5 (CH = N), 133.0 (C-1″), 131.7 (C-3″ & C-5″), 129.4 (C-2″ & C-6″), 123.5 (C-4″), 99.6 (C-1″), 81.2 (C-1′), 76.0 (C-4′), 73.4 (C-5′), 72.7 (C-3′), 71.1 (C-2′), 70.4 (C-3″), 69.7 (C-5″), 68.8 (C-2″), 67.1 (C-4″), 62.4 (C-6′), 60.9 (C-6″), 20.7–20.4 (7×COCH₃); ESI-MS: m/z: 876.41/877.98 [M+H]⁺]/[M+2+H]⁺, 850.47, 828.21, 640.43, 598.38, 331.59; calc. for C₃₄H₄₂⁷⁹BrN₃O₁₇S/C₃₄H₄₂⁸¹BrN₃O₁₇S = 875.14/877.14 Da. Anal. calcd. for C₃₄H₄₂BrN₃O₁₇S: C, 46.58; H, 4.83; N, 4.79; S, 3.66. Found: C, 46.55; H, 4.87; N, 4.82; S, 3.70.

4-Methylbenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5j)

From 709 mg of 3 and 120 mg of 4j. Recrystallized from 96% ethanol to yield white crystals of 5j. Yield: 632 mg, 78% (reaction time: 5 min, procedure A); 786 mg, 97% (reaction time: 2 min, procedure B); mp 177–178°C; $[\alpha]_{D}^{25}$ +94.5 (c 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3212, 1748, 1615, 1373, 1242, 1046; ¹H NMR (DMSO- d_6): δ (ppm) 11.86 (s, 1H, NH-2), 8.59 (d, 1H, J = 9.5 Hz, NH-4), 8.06 (s, 1H, CH = N), 7.69 (d, 2H, J = 8.5 Hz, H-2^{'''} & H-6^{'''}), 7.25 (d, 2H, J =8.5 Hz, H-3^{'''} & H-5^{'''}), 5.84 (t, 1H, J = 9.0 Hz, H-1[']), 5.30 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4"), 5.21 (t, 1H, J = 9.25 Hz, H-2'), 5.15 (dd, 1H, J = 10.25, 3.75 Hz, H-3", 4.88 (t, 1H, J = 9.0 Hz, H-2", 4.80 (d, 1H, J= 8.0 Hz, H-1^{''}), 4.30 (d, 1H, J = 11.0 Hz, H-6'a), 4.25 (t, 1H, J = 6.5 Hz, H-5"), 4.07 (dd, 1H, J = 12.25, 5.75 Hz, H-6'b), 4.04–4.03 (m, 2H, H-6"a & H-6"b), 3.90–3.87 (m, 1H, H-5'), 3.81 (t, 1H, J = 9.5 Hz, H-4'), 2.34 (s, 3H, 4'''-CH₃), 2.11–1.90 (s, 21H, 7×COCH₃); ¹³C NMR (DMSO- d_6): δ (ppm) 178.2 $(C = S), 170.2-169.0 (7 \times COCH_3), 143.9 (CH = N), 140.2 (C-4'''), 131.0 (C-1'''), 131.0 (C-1''), 131.0 (C-1'''), 131.0 (C-1''), 131.0 (C-1''),$ 129.3 (C-3''' & C-5'''), 127.5 (C-2''' & C-6'''), 99.6 (C-1''), 81.2 (C-1'), 76.0 (C-4'), 73.4 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.4 (C-3"), 69.7 (C-5"), 68.9 (C-2"), 67.1 (C-4''), 62.3 (C-6'), 60.9 (C-6''), 20.6–20.2 $(7 \times COCH_3)$, 21.0 $(4'''-CH_3)$; ESI-MS: *m*/*z*: 812.25 [M+H]⁺, 834.31 [M+Na]⁺, 770.31, 640.45, 598.44, 331.34; calc. for $C_{35}H_{45}N_3O_{17}S = 811.25$ Da. Anal. calcd. for $C_{35}H_{45}N_3O_{17}S$: C, 51.78; H, 5.59; N, 5.18; S, 3.95. Found: C, 51.82; H, 5.56; N, 5.16; S, 3.99.

$4 ext{-} Isopropylbenzaldehyde$

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5k)

From 709 mg of **3** and 148 mg of **4k**. Recrystallized from 96% ethanol to yield white crystals of **5k**. Yield: 604 mg, 72% (reaction time: 5 min, procedure A); 814 mg, 97% (reaction time: 2 min, procedure B); mp 148–149°C; $[\alpha]_D^{25}$ +95.4 (*c* 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3501, 3337, 1749, 1610, 1375, 1230, 1049; ¹H NMR (DMSO-*d*₆): δ (ppm) 11.87 (s, 1H, NH-2), 8.57 (d, 1H, J = 9.0 Hz,

NH-4), 8.09 (s, 1H, CH = N), 7.72 (d, 2H, J = 8.0 Hz, H-2^{'''} & H-6^{'''}), 7.30 (d, 2H, J = 8.0 Hz, H-3^{'''} & H-5^{'''}), 5.83 (t, 1H, J = 9.25 Hz, H-1'), 5.30 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4"), 5.18 (t, 1H, J = 9.5 Hz, H-2'), 5.15 (dd, 1H, J = 10.5, 3.75 Hz, H-3"), 4.88 (t, 1H, J = 9.75 Hz, H-2"), 4.80 (d, 1H, J = 8.0 Hz, H-1''), 4.30 (d, 1H, J = 11.5 Hz, H-6'a), 4.25 (t, 1H, J)= 5.75 Hz, H-5"), 4.09–4.03 (m, 3H, H-6'b, H-6"a & H-6"b), 3.88–3.87 (m, 1H, H-5'), 3.81 (t, 1H, J = 9.25 Hz, H-4'), 2.92 [q, 1H, J = 7.0 Hz, $4'''-CH(CH_3)_2$], 2.11–1.90 (s, 21H, $7 \times COCH_3$), 1.21 [d, 6H, J = 7.0 Hz, 4'''-CH(CH₃)₂]; ¹³C NMR (DMSO- d_6): δ (ppm) 178.2 (C = S), 170.2–169.0 (7×COCH₃), 150.9 (C-4"''), 143.8 (CH = N), 131.4 (C-1"''), 127.6 (C-2"'' & C-6"''), 126.6 (C-3"'' & C-6"'') 5'''), 99.6 (C-1''), 81.1 (C-1'), 76.0 (C-4'), 73.4 (C-5'), 72.7 (C-3'), 71.0 (C-2'), 70.3 (C-3"), 69.7 (C-5"), 68.8 (C-2"), 67.1 (C-4"), 62.3 (C-6'), 60.9 (C-6"), 33.4 [4"- $CH(CH_3)_2$], 23.5 [4^{'''}-CH(CH_3)₂], 20.6–20.2 (7×CO CH_3); ESI-MS: m/z: 862.41 $[M+Na]^+$, 848.66, 820.68, 732.72, 596.04, 351.28; calc. for $C_{37}H_{49}N_3O_{17}S =$ 839.28 Da. Anal. calcd. for C₃₇H₄₉N₃O₁₇S: C, 52.91; H, 5.88; N, 5.00; S, 3.82. Found: C, 52.95; H, 5.85; N, 5.03; S, 3.86.

4-Methoxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (51)

From 709 mg of 3 and 136 mg of 4l. Recrystallized from 96% ethanol to yield white crystals of 5l. Yield: 645 mg, 78% (reaction time: 5 min, procedure A); 802 mg, 97% (reaction time: 2 min, procedure B); mp 198–199°C; $[\alpha]_{D}^{25}$ +97.3 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3348, 3284, 1737, 1604, 1370, 1228, 1044; ¹H NMR (DMSO- d_6): δ (ppm) 11.81 (s, 1H, NH-2), 8.55 (d, 1H, J = 9.0 Hz. NH-4), 8.05 (s, 1H, CH = N), 7.75 (d, 2H, J = 8.5 Hz, H-2^{'''} & H-6^{'''}), 6.99 (d, 2H, J = 8.5 Hz, H-3^{'''} & H-5^{'''}), 5.83 (t, 1H, J = 9.25 Hz, H-1'), 5.30 (t, 1H, 2H) J = 9.0 Hz, H-3'), 5.24 (d, 1H, J = 3.0 Hz, H-4''), 5.18 (t, 1H, J = 9.25 Hz, H-2'), 5.15 (dd, 1H, J = 10.0, 3.0 Hz, H-3''), 4.88 (t, 1H, J = 9.25 Hz, H-2''), 4.80 (d, 1H, J = 7.5 Hz, H-1"), 4.30 (d, 1H, J = 11.5 Hz, H-6'a), 4.24 (t, 1H, J) J = 6.75 Hz, H-5", 4.09–4.05 (m, 1H, H-6'b), 4.04–4.03 (m, 2H, H-6"a & H-6"b), 3.89-3.87 (m, 1H, H-4'), 3.82-3.79 (m, 1H, H-5'), 3.81 (s, 3H, 4"'-OMe), 2.11–1.91 (s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 177.8 (C = S), $170.5-169.4 (7 \times COCH_3), 161.1 (C-4'''), 144.1 (CH = N), 129.2 (C-2''' \& C-6'''), 144.1 (CH = N), 129.2 (C-2''' \& C-6''), 144.1 (CH = N), 1$ 126.0 (C-1""), 114.2 (C-3"" & C-5""), 99.6 (C-1"), 81.1 (C-1"), 75.9 (C-4"), 73.5 (C-5'), 72.6 (C-3'), 70.9 (C-2'), 70.3 (C-3''), 69.7 (C-5''), 68.8 (C-2''), 67.1 (C-4''), 62.2 (C-6'), 60.9 (C-6"), 20.5–20.1 (7×COCH₃), 55.2 (4"'-OCH₃); ESI-MS: m/z: 850.28 [M+Na]⁺, 828.23 [M+H]⁺, 786.26, 768.35, 640.38, 540.36, 331.27; calc. for $C_{35}H_{45}N_3O_{18}S = 827.24$ Da. Anal. calcd. for $C_{35}H_{45}N_3O_{18}S$: C, 50.78; H, 5.48; N, 5.08; S, 3.87. Found: C, 50.82; H, 5.45; N, 5.12; S, 3.85.

3-Methoxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5m)

From 709 mg of **3** and 136 mg of **4m**. Recrystallized from 96% ethanol to yield white crystals of **5m**. Yield: 604 mg, 73% (reaction time: 5 min, procedure

A); 761 mg, 92% (reaction time: 2 min, procedure B); mp 196–197°C; $[\alpha]_D^{25}$ +95.8 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3345, 3160, 1747, 1605, 1376, 1241, 1042; ¹H NMR (DMSO- d_6): δ (ppm) 11.95 (s, 1H, NH-2), 8.62 (d, 1H, J = 9.0 Hz, NH-4), 8.07 (s, 1H, CH = N), 7.44 (s, H-2^{'''}), 7.34 (d, 1H, J = 8.0 Hz, H-5^{'''}), 7.31 (d, 1H, J = 8.0 Hz, H-6''), 7.00 (dd, 1H, J = 8.0, 1.5 Hz, H-4''), 5.79 (t, 1H, J)= 9.0 Hz, H-1'), 5.31 (t, 1H, J = 9.25 Hz, H-3'), 5.18 (t, 1H, J = 9.25 Hz, H-2'), 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 7.5 Hz, H-1"), 4.30 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.79 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H-2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 Hz, H=2"), 4.70 (d, 1H, J = 10.0, 3.0 (d, 2H, Jz, Jz, Jz, 11.0 Hz, H-6'a), 4.24 (t, 1H, J = 6.75 Hz, H-5''), 4.07 (dd, 1H, J = 12.5, 6.75 Hz, H-6'b), 4.04 (d, 1H, J = 6.5 Hz, H-6''a), 4.03 (d, 1H, J = 6.5 Hz, H-6''b), 3.88 (ddd, 1H, J = 10.0, 5.5, 3.5 Hz, H-5'), 3.83 (s, 3H, 3'''-OCH₃), 3.81 (t, 1H, J = 9.0 Hz, H-4'), 2.11–2.01 (s, 21H, $7 \times \text{COCH}_3$); ¹³C NMR (DMSO- d_6): δ (ppm) $178.4 (C = S), 170.2-169.0 (7 \times COCH_3), 159.6 (C-3''), 143.5 (CH = N), 135.1$ (C-1^{'''}), 129.6 (C-5^{'''}), 120.7 (C-6^{'''}), 116.5 (C-4^{'''}), 111.4 (C-2^{'''}), 99.6 (C-1^{''}), 81.2 (C-1'), 76.1 (C-4'), 73.4 (C-5'), 72.5 (C-3'), 70.9 (C-2'), 70.4 (C-3''), 69.7 (C-5''), $68.8 (C-2''), 67.1 (C-4''), 62.3 (C-6'), 60.9 (C-6''), 20.6-20.2 (7 \times COCH_3), 55.2$ (3"-OCH₃); ESI-MS: *m*/*z*: 850.28 [M+Na]⁺, 828.27 [M+H]⁺, 786.33, 744.50, 656.21, 445.47, 331.37; calc. for $C_{35}H_{45}N_3O_{18}S = 827.24$ Da. Anal. calcd. for C₃₅H₄₅N₃O₁₈S: C, 50.78; H, 5.48; N, 5.08; S, 3.87. Found: C, 50.76; H, 5.50; N, 5.12; S, 3.91.

2-Methoxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5n)

From 709 mg of 3 and 136 mg of 4n. Recrystallized from 96% ethanol to yield white crystals of **5n**. Yield: 604 mg, 73% (reaction time: 5 min, procedure A); 802 mg, 97% (reaction time: 2 min, procedure B); mp 153–155°C; $[\alpha]_{D}^{25}$ +94.8 (c 1.0, CHCl₃); FTIR (KBr) v / cm⁻¹: 3548, 3282, 1750, 1607, 1372, 1241, 1054; ¹H NMR (DMSO- d_6): δ (ppm) 11.89 (s, 1H, NH-2), 8.58 (d, 1H, J = 9.0 Hz, NH-4), 8.45 (s, 1H, CH = N), 8.06 (d, 1H, J = 8.0 Hz, H-6^{''}), 7.08 (d, 1H, J = 8.5 Hz, H-3'''), 7.42 (t, 1H, J = 7.25 Hz, H-4'''), 6.99 (t, 1H, J = 7.5 Hz, H-5'''), 5.84 (t, 1H, J = 9.0 Hz, H-1', 5.30 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.0 Hz, H-3'), 5.24 (d, $1H, J = 3.0 Hz, H_3'$), 5.24 (d, $1H, J = 3.0 Hz, H_3'$), 5.24 (d, 1H,4''), 5.18 (t, 1H, J = 9.0 Hz, H-2'), 5.16 (dd, 1H, J = 10.0, 3.5 Hz, H-3''), 4.88 (t, 1H, J = 9.0 Hz, H-2"), 4.79 (d, 1H, J = 8.0 Hz, H-1"), 4.31 (d, 1H, J = 11.5 Hz, H-6'a), 4.25 (t, 1H, J = 6.25 Hz, H-5''), 4.07 (dd, 1H, J = 12.5, 5.5 Hz, H-6'b), 3.89-3.78 (m, 1H, H-5'), 4.04-4.03 (m, 2H, H-6''a & H-6''b), 3.88 (ddd, 1H, J =10.0, 5.5, 3.5 Hz, H-4'), 3.83 (s, 3H, 2"'-OCH₃), 2.11–1.90 (s, 21H, 7×COCH₃); ¹³C NMR (DMSO- d_6): δ (ppm) 178.2 (C = S), 170.2–169.1 (7×COCH₃), 158.1 (C-3'''), 139.5 (CH = N), 131.8 (C-1'''), 126.2 (C-5'''), 121.8 (C-6'''), 120.6 (C-6'') 2""), 111.8 (C-4""), 99.6 (C-1"), 81.2 (C-1'), 76.1 (C-4'), 73.4 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.4 (C-3''), 69.8 (C-5''), 68.9 (C-2''), 67.1 (C-4''), 62.4 (C-6'), 61.0 (C-6"), 55.7 (2"'-OCH₃), 20.6–20.2 (7×COCH₃); ESI-MS: m/z: 850.25 [M+Na]⁺, $828.36 [M+H]^+, 763.47, 689.58, 615.57, 429.29, 331.72; calc. for C_{35}H_{45}N_3O_{18}S$ = 827.24 Da. Anal. calcd. for $C_{35}H_{45}N_3O_{18}S$: C, 50.78; H, 5.48; N, 5.08; S, 3.87. Found: C, 50.81; H, 5.46; N, 5.05; S, 3.86.

4-Hydroxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (50)

From 709 mg of 3 and 122 mg of 40. Recrystallized from 96% ethanol to yield white crystals of 50. Yield: 634 mg, 78% (reaction time: 5 min, procedure A); 788 mg, 97% (reaction time: 2 min, procedure B); mp 161–162°C; $[\alpha]_{D}^{25}$ +84.8 $(c 1.0, CHCl_3); FTIR (KBr) \nu / cm^{-1}: 3548, 3340, 3275, 1749, 1609, 1372, 1238,$ 1042; ¹H NMR (DMSO-*d*₆): δ (ppm) 11.76 (s, 1H, NH-2), 9.97 (s, 1H, 4^{'''}-OH), 8.51 (d, 1H, J = 9.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.64 (d, 2H, J = 8.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.64 (d, 2H, J = 8.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.64 (d, 2H, J = 8.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.64 (d, 2H, J = 8.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.64 (d, 2H, J = 8.5 Hz)H-3''' & H-5'''), 6.81 (d, 2H, J = 8.5 Hz, H-2''' & H-6'''), 5.83 (t, 1H, J = 9.25 Hz, H-1'), 5.30 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.18 (t, 1H, J) J = 9.25 Hz, H-2'), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 4.87 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 4.0 Hz, H-3''), 5.16 (dd, 1H, J = 10.0, 5.03.0 Hz, H-2"), 4.80 (d, 1H, J = 8.0 Hz, H-1"), 4.30 (d, 1H, J = 11.0 Hz, H-6'a), 4.25 (t, 1H, J = 6.75 Hz, H-5"), 4.06 (dd, 1H, J = 9.5, 5.5 Hz, H-6b), 4.03-4.02(m, 2H, H-6"a & H-6"b), 3.89-3.86 (m, 1H, H-4"), 3.80 (t, 1H, J = 9.75 Hz, H-5'), 2.11–1.90 (s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 177.7 (C = S), $170.2-169.0 (7 \times COCH_3), 159.6 (C-4'''), 144.1 (CH = N), 129.4 (C-2''' \& C-6'''),$ 124.6 (C-1""), 115.6 (C-3"" & C-5""), 99.6 (C-1"), 81.1 (C-1'), 76.1 (C-4'), 73.3 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.3 (C-3''), 69.7 (C-5''), 68.8 (C-2''), 67.1 (C-4''), $62.3 (C-6'), 60.9 (C-6''), 20.7-20.3 (7 \times COCH_3); ESI-MS: m/z: 836.31 [M+Na]^+, 60.9 (C-6''), 20.7-20.3 (7 \times COCH_3); ESI-MS: m/z: 836.31 [M+Na]^+, 60.9 (C-6''), 80.9 (C-6''), 80.9$ $814.22 [M+H]^+$, 772.33, 640.45, 598.45, 427.05, 331.45; calc. for $C_{34}H_{43}N_3O_{18}S$ = 813.23 Da. Anal. calcd. for $C_{34}H_{43}N_3O_{18}S$: C, 50.18; H, 5.33; N, 5.16; S, 3.94. Found: C, 50.22; H, 5.31; N, 5.19; S, 3.91.

2-Hydroxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5p)

From 709 mg of **3** and 122 mg of **4p**. Recrystallized from 96% ethanol to yield white crystals of **5p**. Yield: 504 mg, 62% (reaction time: 5 min, procedure A); 788 mg, 97% (reaction time: 2 min, procedure B); mp 150–151°C; $[\alpha]_D^{25}$ +85.9 (c 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3602, 3446, 3282, 1741, 1609, 1372, 1228, 1040; ¹H NMR (DMSO-d₆): δ (ppm) 11.74 (s, 1H, NH-2), 9.96 (s, 1H, 2″′OH), 8.49 (d, 1H, J = 9.5 Hz, NH-4), 8.00 (s, 1H, CH = N), 7.63 (d, 2H, J = 8.5 Hz, H-4″′ & H-6″′′), 6.81 (d, 2H, J = 8.5 Hz, H-3″′ & H-5″′′), 5.83 (t, 1H, J = 9.25 Hz, H-1′), 5.29 (t, 1H, J = 9.25 Hz, H-3′′ , 5.24 (d, 1H, J = 3.5 Hz, H-4″′, 5.15 (dd, 1H, J = 3.75, 9.75 Hz, H-2′), 5.11 (t, 1H, J = 9.0 Hz, H-3″′), 4.87 (dd, 1H, J = 10.0, 3.0 Hz, H-2′′), 4.79 (d, 1H, J = 8.0 Hz, H-1″), 4.30 (d, 1H, J = 11.5 Hz, H-6′a), 4.24 (t, 1H, J = 6.75 Hz, H-5″′), 4.06 (dd, 1H, J = 12.0, 5.5 Hz, H-6′b), 4.04–4.02 (m, 2H, H-6″a & H-6″b), 3.89–3.86 (m, 1H, H-5′), 3.80 (t, 1H, J = 9.5 Hz, H-4′′, 2.11–1.90 (s, 21H, 7×COCH₃); ¹³C NMR (DMSO-d₆): δ (ppm) 177.8 (C = S), 170.2–169.1 (7×COCH₃), 159.7 (C-2″′), 144.2 (CH = N), 129.4 (C-4″′ & C-6″′′), 124.7 (C-5″′′), 115.6 (C-1″′ & C-3″′′), 99.6 (C-1″), 81.1 (C-1′), 76.1 (C-4′)

73.4 (C-5'), 72.7 (C-3'), 71.1 (C-2'), 70.4 (C-3''), 69.8 (C-5''), 68.9 (C-2''), 67.2 (C-4''), 62.4 (C-6'), 61.0 (C-6''), 20.7–20.3 (7×COCH₃); ESI-MS: m/z: 836.39 [M+Na]⁺, 814.50 [M+H]⁺, 794.62, 659.65, 606.01, 561.97, 430.45, 342.45; calc. for C₃₄H₄₃N₃O₁₈S = 813.23 Da. Anal. calcd. for C₃₄H₄₃N₃O₁₈S: C, 50.18; H, 5.33; N, 5.16; S, 3.94. Found: C, 50.15; H, 5.31; N, 5.19; S, 3.98.

3-Methoxy-4-hydroxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5q)

From 709 mg of **3** and 152 mg of **4q**. Recrystallized from 96% ethanol to yield white crystals of 5q. Yield: 649 mg, 77% (reaction time: 5 min, procedure A); 817 mg, 97% (reaction time: 2 min, procedure B); mp 187–188°C; $[\alpha]_{D}^{25}$ +101.4 (c 1.0, CHCl₃); FTIR (KBr) ν / cm⁻¹: 3480, 3337, 1749, 1603, 1377, 1224, 1051; ¹H NMR (DMSO-*d*₆): δ (ppm) 11.84 (s, 1H, NH-2), 9.57 (s, 1H, 4^{'''}-OH), 8.50 (d, 1H, J = 9.0 Hz, NH-4), 7.98 (s, 1H, CH = N), 7.46 (d, J = 1.5 Hz, H-2''),7.10 (dd, 1H, J = 8.25, 1.5 Hz, H-6^{'''}), 6.81 (d, 1H, J = 8.0 Hz, H-5^{'''}), 5.74 (t, 1H, J = 9.25 Hz, H-1'), 5.33 (t, 1H, J = 9.25 Hz, H-3'), 5.24 (d, 1H, J = 3.5 Hz, H-4''), 5.17–5.13 (m, 2H, H-2' & H-3''), 4.87 (dd, 1H, J = 10.0, 3.0 Hz, H-2''), 4.78 (d, 1H, J = 8.0 Hz, H-1"), 4.29 (d, 1H, J = 11.0 Hz, H-6"), 4.25 (t, 1H, J= 6.75 Hz, H-5"), 4.07 (dd, 1H, J = 12.0, 5.5 Hz, H-6"), 4.04–4.02 (m, 2H, H-6") 6"a & H-6"b), 3.86 (s, 3H, 3"-OMe), 3.85–3.81 (m, 2H, H-4' & H-5'), 2.11–1.91 (s, 21H, $7 \times COCH_3$); ¹³C NMR (DMSO- d_6): δ (ppm) 177.8 (C = S), 170.2–169.0 $(7 \times COCH_3)$, 149.5 (C-4^{'''}), 147.1 (C-3^{'''}), 144.1 (CH = N), 125.0 (C-1^{'''}), 122.4 (C-6"), 115.4 (C-5"), 111.1 (C-2"), 99.6 (C-1"), 81.0 (C-1'), 76.2 (C-4'), 73.3 (C-5'), 72.4 (C-3'), 70.8 (C-2'), 70.4 (C-3''), 69.7 (C-5''), 68.8 (C-2''), 67.1 (C-4"), 62.3 (C-6'), 60.9 (C-6"), 55.7 (3"-OCH₃), 20.7–20.3 (7×COCH₃); ESI-MS: m/z: 865.88 [M+Na]⁺, 843.79 [M+H]⁺, 824.00, 806.09, 701.09, 659.10, 424.06, 331.02; calc. for $C_{35}H_{45}N_3O_{19}S = 843.24$ Da. Anal. calcd. for $C_{35}H_{45}N_3O_{19}S$: C, 49.82; H, 5.38; N, 4.98; S, 3.80. Found: C, 49.86; H, 5.35; N, 4.96; S, 3.83.

3- Ethoxy-4-hydroxybenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5r)

From 709 mg of **3** and 166 mg of **4r**. Recrystallized from 96% ethanol to yield white crystals of **5r**. Yield: 659 mg, 77% (reaction time: 5 min, procedure A); 831 mg, 97% (reaction time: 2 min, procedure B); mp 140–142°C; $[\alpha]_D^{25}$ +104.3 (c 1.0, CHCl₃); FTIR (KBr) ν /cm⁻¹: 3539, 3277, 1757, 1734, 1604, 1371, 1240, 1036; ¹H NMR (DMSO-d₆): δ (ppm) 11.80 (s, 1H, NH-2), 9.45 (s, 1H, 4″′-OH), 8.45 (d, 1H, J = 9.0 Hz, NH-4), 7.97 (s, 1H, CH = N), 7.40 (d, 1H, J = 1.5 Hz, H-2″′′), 7.11 (dd, 1H, J = 8.5, 1.5 Hz, H-6″′′), 6.82 (d, 1H, J = 8.5 Hz, H-5″′′), 5.75 (t, 1H, J = 9.0 Hz, H-1′′), 5.31 (t, 1H, J = 9.25 Hz, H-3′′), 5.24 (d, 1H, J = 3.5 Hz, H-4″′), 5.15 (dd, 1H, J = 10.25, 3.75 Hz, H-2′′), 5.13 (t, 1H, J = 9.0 Hz, H-1J = 8.0, 10.5 Hz, H-2″′), 4.78 (d, 1H, J = 8.0 Hz, H-1″), 4.29 (d, 1H, J = 10.5 Hz, H-6′a), 4.25 (t, 1H, J = 12.0, 5.5 Hz, H-5″′′), 4.11 (q, 2H, J = 7.0 Hz, 3″′-OCH₂CH₃), 4.08 (dd, 1H, J = 12.0, 5.5 Hz,

H-6'b), 4.04–4.01 (m, 2H, H-6"a & H-6"b), 3.86 (ddd, 1H, J = 10.0, 5.5, 1.5 Hz, H-5'), 3.81 (t, 1H, J = 9.25 Hz, H-4'), 2.11–1.90 (s, 21H, $7 \times COCH_3$), 1.35 (t, 3H, J = 7.0 Hz, 3"'-OCH₂CH₃); ¹³C NMR (DMSO-d₆): δ (ppm) 177.8 (C = S), 170.2–169.0 ($7 \times COCH_3$), 149.6 (C-4"'), 148.1 (C-3"'), 144.3 (CH = N), 125.1 (C-1"'), 122.6 (C-6"'), 115.3 (C-5"'), 109.5 (C-2"'), 99.6 (C-1"), 81.6 (C-1'), 76.1 (C-4'), 73.3 (C-5'), 72.4 (C-3'), 70.8 (C-2'), 70.3 (C-3"), 68.8 (C-2"), 69.7 (C-5"), 67.1 (C-4"), 63.9 (3"'-OCH₂CH₃), 62.2 (C-6'), 60.9 (C-6"), 20.6–20.2 ($7 \times COCH_3$), 14.7 (3"'-OCH₂CH₃); ESI-MS: m/z: 880.10 [M+Na]⁺, 858.08 [M+H]⁺, 803.08, 540.62, 512.74, 429.44, 413.40, 318.51; calc. for C₃₆H₄₇N₃O₁₉S = 857.25 Da. Anal. calcd. for C₃₆H₄₇N₃O₁₉S: C, 50.40; H, 5.52; N, 4.90; S, 3.74. Found: C, 50.43; H, 5.50; N, 4.93; S, 3.72.

4-Dimethylaminobenzaldehyde

N-(2,3,6,2',3',4',6'-hepta-O-acetyl- β -D-lactosyl)thiosemicarbazone (5s)

From 709 mg of 3 and 149 mg of 4s. Recrystallized from 96% ethanol to yield white crystals of 5s. Yield: 655 mg, 78% (reaction time: 5 min, procedure A); 804 mg, 96% (reaction time: 2 min, procedure B); mp 187–188°C; $[\alpha]_{D}^{25}$ $+112.5 (c \ 1.0, \text{CHCl}_3); \text{FTIR} (\text{KBr}) \nu / \text{cm}^{-1}: 3320, 1753, 1604, 1372, 1220, 1054;$ ¹H NMR (DMSO- d_6): δ (ppm) 11.67 (s, 1H, NH-2), 8.41 (d, 1H, J = 9.5 Hz, NH-4), 7.97 (s, 1H, CH = N), 7.59 (d, 2H, J = 8.5 Hz, H-2^{'''} & H-6^{'''}), 6.72 (d, 2H, J = 8.5 Hz, H-3''' & H-5'''), 5.82 (t, 1H, J = 9.0 Hz, H-1'), 5.30 (t, 1H, J = 9.0 Hz, H-3'), 5.25 (d, 1H, J = 2.5 Hz, H-4"), 5.17–5.14 (m, 2H, H-2' & H-3"), 4.88 (t, 1H, J = 9.0 Hz, H-2"), 4.79 (d, 1H, J = 7.5 Hz, H-1"), 4.30 (d, 2H) 1H, J = 11.0 Hz, H-6'a), 4.25 (t, 1H, J = 6.0 Hz, H-5''), 4.09–4.05 (m, 1H, H-6'b), 4.04–4.03 (m, 2H, H-6''a & H-6''b), 3.88–3.85 (m, 1H, H-5'), 3.81 (t, 1H, $J = 9.25 \text{ Hz}, \text{ H-4'}, 2.97 \text{ (s, 6H, 4'''-N(CH_3)_2]}, 2.11-1.91 \text{ (s, 21H, 7} \times \text{COCH}_3);$ ¹³C NMR (DMSO- d_6): δ (ppm) 177.3 (C = S), 170.2–169.0 (7×COCH₃), 151.7 (C-4'''), 144.8 (CH = N), 128.9 (C-2''' & C-6'''), 120.8 (C-1'''), 111.6 (C-3''' & C-5'''), 99.6 (C-1''), 81.1 (C-1'), 76.1 (C-4'), 73.4 (C-5'), 72.7 (C-3'), 71.0 (C-2'), 70.4 (C-3"), 69.7 (C-5"), 68.9 (C-2"), 67.1 (C-4"), 62.3 (C-6"), 60.9 (C-6"), 40.0 $[4'''-N(CH_3)_2]$, 20.6–20.2 (7×COCH₃); ESI-MS: m/z: 863.39 [M+Na]⁺, 841.45 $[M+H]^+, 821.57, 799.47, 577.88, 536.38, 433.16, 331.38; calc. for C_{36}H_{48}N_4O_{17}S_{17}$ = 840.27 Da. Anal. calcd. for $C_{36}H_{48}N_4O_{17}S$: C, 51.42; H, 5.75; N, 6.66; S, 3.81. Found: C, 51.46; H, 5.72; N, 6.64; S, 3.84.

Biological Activity

Antimicrobial activities

All the synthesized compounds **5a–s** were screened for their in vitro antibacterial and antifungal activities by the twofold serial dilution technique using the principles of Clinical and Laboratory Standards Institute.^[58] Antimicrobial activity *in vitro* against *Staphylococcus aureus* (ATCC 11632),

Escherchia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 25923), Klebsiella pneumonia (ATCC 4352), Staphylococcus epidermidis (ATCC 12228), Bacillus subtilis (ATCC 11774), Enterobacter aerogenes (ATCC 13048) were investigated by minimum inhibitory concentration (MIC) using agar dilutions technique using Mueller-Hinton agar medium. Test compounds were dissolved in dimethyl sulfoxide (DMSO) and applied to plates with serially diluted compounds to be tested. The inoculum was prepared using a 4-6-h broth adjusted to a turbidity equivalent of an 0.5 McFarland standard, diluted in broth media to give a final concentration of 5 \times 10 5 CFU/mL in the test tray; they were covered and placed in plastic bags to prevent evaporation. The plates were incubated at 35° C for 18–20 h. The MIC was defined as the lowest concentration of compound giving complete inhibition of visible growth. Sulphamethoxazole and trimethoprim were used as reference (positive control) for bacteria. Also as negative control, antimicrobial effects of the solvents (DMSO) were determined. According to the values of the controls, the results were evaluated. Minimal inhibitory concentrations for each compound were investigated against standard bacterial strains. The MIC values for all test compounds and reference drug are shown in Table 1.

The compounds **5a–s** were also evaluated for their *in vitro* antifungal activity against *Aspergillus niger* (439), *Candida albicans* (ATCC 7754), *Fusarium oxysporum* (M42), *Saccharomyces cerevisiae* (SH20) using agar dilution method with Saburoud's dextrose agar (Hi-Media). Suspensions of each microorganisms were prepared to contain 10 CFU/mL and applied to agar plates which have been serially diluted with compounds to be tested. The plates were incubated at 26°C during 48 h and MIC's were determined.^[58] The MIC values for all test compounds and reference drug are shown in Table 2.

The calculated logP of all synthesized thiosemicarbazones have been obtained by using ACD/LogP in Advanced Chemistry Development (ACD/Labs) Software (*in silico* Prediction of Physicochemical, ADME, and Toxicity Properties, Release 12, 2015).

Statistical analysis

All data on antioxidant activities were the average of triplicate analyses and one-way analysis of variance was performed by ANOVA procedures. Significant differences between means were determined by Duncan's Multiple Range tests and P values <0.05 were regarded as significant and p values <0.01 were very significant.

SUPPLEMENTARY MATERIAL

Supplemental data for this article can be accessed on the publisher's website.

FUNDING

Financial support for this work was provided by Vietnam's National Foundation for Science and Technology Development (NAFOSTED), code 104.01-2013.26.

REFERENCES

1. Karalı, N.; Gürsoy, A.; Kandemirli, F.; Shvets, N.; Kaynak, F.B.; Özbey, S.; Kovalishyn, V. and Dimoglo, A. Synthesis and structure-antituberculosis activity relationship of 1*H*-indole-2,3-dione derivatives. *Bioorg. Med. Chem.* **2007**, *15*, 5888–5904.

2. Cocco, M.; Congiu, T.C.; Onnis, V.; Pellerano, M.L. and de Logu, A. Synthesis and antimycobacterial activity of new S-alkylisothiosemicarbazone derivatives. *Bioorg. Med. Chem.* **2002**, *10*, 501–506.

3. de Aquino, T.M.; Liesen, A.P.; da Silva, R.E.; Lima, A.V.; Carvalho, T.C.S.; de Faria, A.R.; de Araújo, J. M.; de Lima, J.G.; Alves, A.J.; de Melo, E.J.T. and Góes, A.J.S. Synthesis, anti-*Toxoplasma gondii* and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids. *Bioorg. Med. Chem.* **2008**, *16*, 446–456.

4. Cukurovali, A.; Yilmaz, I.; Gur, S.; Kazaz, C. Synthesis, antibacterial and antifungal activity of some new thiazolylhydrazone derivatives containing 3-substituted cyclobutane ring. *Eur. J. Med. Chem.* **2006**, *41*, 201–207.

5. Hall, M.D.; Salam, N.K.; Hellawell, J.L.; Fales, H.M.; Kensler, C.B.; Ludwig, J.A.; Szakács, G.; Hibbs, D.E. and Gottesman, M.M. Synthesis, activity, and pharmacophore development for isatin- β -thiosemicarbazones with selective activity toward multidrug-resistant cells. *J. Med. Chem.* **2009**, *52*, 3191–3204.

6. Ali, A.Q.; Teoh, S.G.; Salhin, A.; Eltayeb, N.E.; Ahamed, M.B.K.; Abdul Majid, A.M.S. Synthesis of isatin thiosemicarbazones derivatives: *In vitro* anti-cancer, DNA binding and cleavage activities. *Spectrochim. Acta Part A: Mol. Biomol. Spec.* **2014**, *125*, 440–448.

7. Aly, M.M.; Mohamed, Y.A.; El-Bayouki, K. A. M.; Basyouni, W. M.; Abbas, S. Y. Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and antimicrobial activities-Part-1. *Eur. J. Med. Chem.* **2010**, *45*, 3365–3373.

8. Yanardag, R.; Demirci, T.B.; Ülküseven, B.; Bolkent, S.; Tunali, S.; Bolkent, S. Synthesis, characterization and antidiabetic properties of N^{1} -2,4-dihydroxybenzylidene- N^{4} -2-hydroxybenzylidene-S-methyl-thiosemicarbazidato-oxovanadium(IV). *Eur. J. Med. Chem.* **2009**, *44*, 818–826.

9. Thanusu, J.; Kanagarajan, V.; Gopalakrishnan, M. Synthesis, spectral analysis and in 38 microbiological evaluation of 3-(3-alkyl-2,6-diarylpiperin-4-ylidene)-2-thioxoimidazolidin-4-ones as a new class of antibacterial and antifungal agents. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 713–717.

10. Vandresen, F.; Falzirolli, H.; Batista, S. A. A.; da Silva-Giardini, A. P. B.; de Oliveira, D. N.; Catharino, R. R.; Ruiz, A.L.T.G.; de Carvalho, J.E.; Foglio, M.A.; da Silva, C.C. Novel R-(+)-limonene-based thiosemicarbazones and their antitumor activity against human tumor cell lines. *Eur. J. Med. Chem.* **2014**, 79, 110–116.

11. Quiroga, A.G.; Ranninger, C.N. Contribution to the SAR field of metallated and coordination complexes: Studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. *Coord. Chem. Rev.* **2004**, *248*, 119–133.

12. Karalı, N. Synthesis and primary cytotoxicity evaluation of new 5-nitroindole-2, 3-dione derivatives. *Eur. J. Med. Chem.* **2002**, *37*, 909–918.

13. Nguyen, D.T.; Le, T.H.; Bui, T.T.T. Antioxidant activities of thiosemicarbazones from substituted benzaldehydes and N-(tetra-O-acetyl- β -d-glucopyranosyl)thiosemicarbazide. *Eur. J. Med. Chem.* **2013**, 60, 199–207.

14. Bal-Demirci, T.; Şahin, M.; Kondakçı, E.; Özyürek, M.; Ülküseven, B.; Apak, R. Synthesis and antioxidant activities of transition metal complexes based 3hydroxysalicylaldehyde-S-methylthiosemicarbazone. Spectrochim. Acta Part A: Mol. Biomol. Spec. **2015**, 138, 866–872.

15. Ghosh, S.; Misra, A.K.; Bhatia, G.; Khan, M.M.; Khanna, A.K. Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 386–389.

16. Alexacou, K.-M.; Tenchiu (Deleanu), A.-C.; Chrysina, E.D.; Charavgi, M.-D.; Kostas, I.D.; Zographos, S.E.; Oikonomakos, N.G.; Leonidas, D.D. The binding of β -d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors. *Bioorg. Med. Chem.* **2010**, *18*, 7911–7922.

17. Witczak, Z.J. Monosaccharides thio- and isothiocyanates: Synthesis, chemistry and preparative application. In *Advances in Carbohydrate Chemistry and Biochemistry*; Tipson, S., Ed.; Academic Press: New York, 1986; Vol. 44, 91–145.

18. Witczak, Z.J. Desulfurization of glycosyl isothiocyanates with tributyltin hydride. *Tetrahedron Lett.* **1986**, *27*, 155–158.

19. Alho, M.A.M.; d'Accorso, N.B. Behavior of free sugar thiosemicarbazones toward heterocyclization reactions. *Carbohydr. Res.* **2000**, *328*, 481–488.

20. van de Kamp, F.-P.; Micheel, F. Über d-glucose-derivate von thiosemicarbazonen und ihre biologische wirksamkeit. *Chem. Ber.* **1956**, *89*, 133–140.

21. Bognár, R.; Somogyi, L.; Szilágyi, L.; Györgydeák, Z. N-Glykosyl-Derivate: Teil XIII. Der nachträgliche ausbau des aglykons. Synthese von N-Glykosyl-Derivaten des 2-amino-thiazols, 2-amino-1,3,4-thiadiazols und 5-amino-1,2,3,4-thiatriazols. *Carbohydr. Res.* **1967**, *5*, 320–328.

22. Wójtowicz, M.; Gmernicka-Haftek, C.; Wieniawski, W. Synthesis of $4-\beta$ -d-glucopyranosyl-3-thiosemicarbazones of some aromatic aldehydes. *Acta Pol. Pharm.* **1975**, 32, 49–52.

23. Tashpulatov, A.A.; Afanas'ev, V.A.; Lidak, M.Yu.; Sukhova, N.M.; Popelis, Yu.Yu. and Rakhmatullaev, I. Synthesis and transformations of carbohydrate derivatives. I. Synthesis of furan and 5-nitrofuran derivatives of some thiosemicarbazones and thiosemicarbazides of d-glucose and l-arabinose. *Chem. Heterocycl. Comp.* **1983**, *19*, 137–141.

24. Tashpulatov, A.A.; Rakhmatullaev, V.A.; Ismailov, N. Synthesis and some reactions of glycosyl isocyanate. *Zh. Org. Khim.* **1988**, *24*, 1893–1897. *Chem. Abstr.* **1989**, *111*, 39684m.

25. Yang, B.; Zhang, S.S. and Li, H.X. Synthesis and characterization of novel thiosemicarbazones bearing sugar moieties. *Chem. Res. Chin. Univ.* **2006**, *22*, 738–741.

26. Garnaik, B.K. and Behera, R.K. Antimicrobial & antifungal activities of some 2-arylimino-4-tetra-O-acetyl- β -d-glucopyranosyl-4-thiazolidinones. *Indian J. Chem.* **1988**, 27B, 1157–1158.

27. Tenchiu Deleanu, A.C.; Kostas, I.D.; Kovala-Demertzi, D.; Terzis, A. Synthesis and characterization of new aromatic aldehyde/ketone 4-(β -d- glucopyranosyl)thiosemicarbazones. *Carbohydr. Res.* **2009**, *344*, 1352–1364.

28. Thanh, N.D.; Giang, N.T.K.; Hoai, L.T. Microwave-assisted synthesis of acetophenone (per-O-acetylated- β -d- glucopyranosyl)thiosemicarbazones. *E-J. Chem.* **2010**, 7, 899–907.

29. Freemantle, M. Ionic liquids may boost clean technology development. *Chem. Eng. News* **1998**, *76*, 32–37.

30. Larsen, A.S.; Holbrey, J.D.; Tham, F.S.; Reed, C.A. Designing ionic liquids: Imidazolium melts with inert carborane anions. *J. Am. Chem. Soc.* **2000**, *122*, 7264–7272.

31. Gordon, C.M. and Muldoon, M.J. Synthesis and purification. In *Ionic Liquids in Synthesis*; Wasserscheid, P. and Welton, T., Eds.; WILEY-VCH: Weinheim, 2008; Vol. 1, 7–56.

32. Wilkes, J.S. Properties of ionic liquid solvents for catalysis. J. Mol. Catal. A: Chem. **2004**, 214, 11–17.

33. Cole, A.C.; Jensen, J.L.; Ntai, I.; Tran, K.L.T.; Weaver, K.J.; Forbes, D.C.; Davis Jr, J.H. Novel Brønsted acidic ionic liquids and their use as dual solvent-catalysts. *J. Am. Chem. Soc.* **2002**, *124*, 5962–5963.

34. Corsaro, A.; Chiacchio, U.; Pistarà, V., and Romeo, G. Microwave-assisted chemistry of carbohydrates. In *Microwave in organic synthesis*, 2nd ed.; Loupy, A., Ed.; WILEY-VCH: Weinheim, Germany, 2006; Vol.1, 579–594.

35. Furniss, B.S.; Hannaford, A.J.; Smith, P.W.G.; Tatchell, A.R. Vogel's Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, 5th ed., Longman: London, 1989; pp. 963–968.

36. Zhang, S.-S.; Yang, B.; Li, J.-Z.; Li, X.-M.; Jie, G.-F.; Jiao, K. Synthesis, characterization and electrochemical behavior of hepta-O-acetyl- β -lactosyl isothiocyanate. *Chin. J. Chem.* **2005**, *23*, 543–547.

37. Dandale, A.S.; Mangteb, D.V. and Deshmukha, S.P. Synthesis of N- and S-bisprotected lactosyl isothiobiurets. *Carbohydr. Res.* **2007**, *342*, 753–756.

38. Garciáa-Moreno, M.I.; Diáaz-Pérez, P.; Benito, J.M.; Ortiz Mellet, C.; Defaye, J.; Garciáa Fernánde, J.M. One-step synthesis of non-anomeric sugar isothiocyanates from sugar azides. *Carbohydr. Res.* **2002**, *337*, 2329–2334.

39. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A.-L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S.M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. *J. Med. Chem.* **2004**, *47*, 935–946.

40. Gulcin, I.; Buyukokuroglu, M.E.; Oktay, M.; Kufrevioglu, O.I. In vitro antioxidative properties of melatonin. *J. Pineal Res.* **2002**, *33*, 167–171.

41. Lai, L.-S.; Chou, S.-T. and Chao, W.-W. Studies on the antioxidative activities of Hsian-tsao (*Mesona procumbens* Hemsl) leaf gum. *J. Agric. Food Chem.* **2001**, *49*, 963–968.

42. Niki, E. Assessment of antioxidant capacity *in vitro* and *in vivo*. *Free Radic*. *Biol*. *Med.* **2010**, *49*, 503–515.

43. Ma, M.; Cheng, Y.; Xu, Z.; Xu, P.; Qu, H.; Fang, Y.; Xu, T.; Wen, L. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. *Eur. J. Med. Chem.* **2007**, *42*, 93–8.

44. Heaslet, H.; Harris, M.; Fahnoe, K.; Sarver, R.; Putz, H.; Chang, J.; Subramanyam, C.; Barreiro, G.; Miller, J.R. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus *in complex with the potent inhibitor trimethoprim. Proteins* **2009**, *76*, 706–717.

45. Alsaad, N.; van Altena, R.; Pranger, A.D.; van Soolingen, D.; de Lange, W.C.; van der Werf, T.S.; Kosterink, J.G.; Alffenaar, J.W. *Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur. Respir. J.* **2013**, *42*, 504–512.

46. Wormser, G.P.; Keusch, G.T.; Heel, R.C. Co-trimoxazole (trimethoprimsulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. Drugs **1982**, 24, 459–518.

47. Laurence, A.; Moran, L.A.; Horton, H.R.; Scrimgeour, K.G.; Perry, M.D. In *Principles of Biochemistry*, 5th Ed., Pearson: Boston, 2012: 134–195.

48. Marieb, E.N.; Hoehn, H. *Human Anatomy and Physiology*, 9th Ed., Pearson: Toronto; 2013, p. 643.

49. World Health Organization (WHO). WHO Model List of Essential Medicines. 2013. Available at: http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf? ua=1. Accessed November 13, 2015.

50. Owens, G.S.; Adu-Omar, M.M. Comparative kinetic investigations in ionic liquids using the MTO/peroxide system. *J. Mol. Cat.* **2002**, *187*, 215–225.

51. Wang, C.; Guo, L.; Li, H.; Wang, Y.; Weng, J. and Wu, L. Preparation of simple ammonium ionic liquids and their application in the cracking of dialkoxypropanes. *Green Chem.* **2006**, *8*, 603–607.

52. Singh, V.; Kaur, S.; Sapehiyia, V.; Singh, J.; Kad, G.L. Microwave accelerated preparation of [Bmim][HSO4] ionic liquid: an acid catalyst for improved synthesis of coumarins. *Cat. Commun.* **2005**, *6*, 57–60.

53. Bicak, N. A new ionic liquid: 2-hydroxy ethylammonium formate. J. Mol. Liq. **2005**, 116, 15–18.

54. Wu, Q.; Chen, H.; Han, M.; Wang, D. and Wang, J. Transesterification of cottonseed oil catalyzed by Brønsted acidic ionic liquids. *Ind. Eng. Chem. Res.* **2007**, *46*, 7955–7960.

55. Joseph, T.; Sahoo, S.S.; Halligudi, B. Brönsted acidic ionic liquids: A green, efficient and reusable catalyst system and reaction medium for Fischer esterification. *J. Mol. Cat.* **2005**, *234*, 107–110.

56. Lemieux, R.L. Tetra-O-acetyl-β- d- glucopyranosyl bromide, In *Methods in Carbohydrate Chemistry*; Whistler, R.L.; Wolform, M.L., Eds.; Academic Press: New York, 1963; Vol. 2: 221–222.

57. Yadgire, A.V.; Korpe, G.V. and Deshmukh, S.P. Comparative study of microwave induced and conventional synthesis of acetylated sugar isothiocyanates and related thiocarbamides. *E-J. Chem.* **2011**, *8*, 1614–1619.

58. Espinel, S.S. *Manual of Clinical Microbiology*, American Society for Microbiology: Washington, DC, 1980.